Cover: Shows RCPA Forensic Pathologist Dr Rohan Samarasinghe teaching in Suva, Fiji, as part of the RCPA’s Pathology Education Outreach program. Dr Samarasinghe focussed on histology and post-mortem techniques. His knowledge and skills were of great value and well received by the local Pathologists and Trainees.
Contents

President’s Perspective 2
Report Summary 4
Review of Operations 6
RCPA Foundation 8
Pathology Journal 9
RCPA Communications 10
RCPA Events 12
Special Events 20
Fellowships Awarded 25
Awards Presented 27
Information on Directors 28
Meetings of the Board of Directors 31
Vale 32
Obituaries 33
Indemnifying Officers or Auditor 43
Proceedings on Behalf of College 44
Directors’ Declaration 45
Auditors Independence Declaration 46
Statement of Profit or Loss and other comprehensive Income 47
Statement of Financial Position 48
Statement of Cash Flows 49
Statement of Changes in Equity 50
Notes to the Financial Statements 51
Independent Auditor’s Report 70
The 2018-2019 year has been an interesting and at times difficult one for the College. October 2018 saw Vice President Dr Michael Dray, CEO Dr Debra Graves, and me represent the College at the annual International Liaison of Pathology Presidents meeting which was held in London, hosted by the Royal College of Pathologists. The ILPP includes Colleges from UK, Ireland, Canada, USA, Hong Kong, Malaysia, South Africa as well as Australia. It provides a forum for cooperation and collaboration over many areas of common policy. It is an opportunity to share common problems which seem to arise despite differences in our systems.

On the Australian front, we continue to be represented on the Council of Presidents of Medical Colleges (CPMC) by the CEO and myself.

This Council offers the opportunity to share issues with our fellow Colleges and provides a contact point with many other organisations and Government Health Officers.

The RCPA has conducted a number of meetings and courses during the year. We attended the New Zealand Annual Scientific Meeting which was held in Wellington in September 2018 and was very successful. The 2019 meeting will be held in Queenstown in November and will coincide with the College AGM.

In 2019 Pathology Update was held in the Melbourne Convention and Exhibition Centre. The meeting was again extremely successful with an excellent academic and social program. Congratulations and thanks must go to the organising committees and to the RCPA Events and Sponsorship Manager. In 2020 Pathology Update will return to Sydney and we fully expect the success of the meeting to continue and for it to grow.

November 2018 saw the College Strategic Planning Day, International Pathology Day and the RCPA Annual General Meeting. Dr Lawrie Bott stepped down as Chair of the Board of Professional Practice and Quality after 11 years in the position as Chair of BBPQ and its predecessor. Special thanks must go to Dr Bott for his outstanding contribution.

In 2019 the activities of the College have been dominated by the impending NPAAC Supervision Document and the implications this document has on governance of laboratories. In particular, the College has had to devote significant resources to create curriculum to enable Fellows who are currently supervising molecular laboratories the opportunity to extend their scope of practice within their discipline to continue to be able to run these
laboratories. This has created an immense body of work for the College and the Chief Examiners and other Fellows who volunteered their time. We all owe great thanks for this effort.

The RCPA Foundation continues to slowly grow. The Board’s long-term aim is for the RCPA Foundation to be fully capitalised and self-sustaining so that it can fulfil its role in funding research and teaching.

The Australian political landscape has continued to raise significant hurdles for the pathology profession. The College has maintained a vigorous advocacy role and many College Fellows, including your Board of Directors and Committee members, have been actively involved in interaction with governments (both Federal and State). We are determined to protect the interests of Fellows and of patients. Your representatives have been interacting with Health Ministers, Health Department bureaucrats and the media. The major ongoing issues continue to include the MBS Review, Collection Centre rental issues, and the lack of utility of the MSAC process when it is applied to diagnostic testing. The College has been involved, along with Australian Pathology and Public Pathology Australia, in negotiations with the Federal Department of Health with the aim of forging an Accord about how the recommendations of the MBS review are to be implemented and how the MSAC process can be modified to become more “fit for purpose.”

Workshops have continued with the Medical Board of Australia regarding the creation of a revalidation process for medical practitioners (now renamed the Professional Performance Framework). We remain optimistic that we will end up with a process that is relevant to Pathology and which will fit in with routine work. The RCPA’s changes to the Continuing Professional Development Program have placed us well to comply with the MBA’s proposed processes.

Finally, I would like to thank you, the College Fellows, for your support of College activities, whether it’s volunteering to participate in a myriad of representative roles and tasks or taking part in College organised events. I am also most grateful for the endeavours and commitment of the CEO and all those College employees who support our organisation.

I commend the 2019 annual report to you.

Bruce Latham
President
Board of Directors

Alphabetical list of Directors of the College currently in office.

Dr Lawrence Bott (until November 2018)
Prof John Burnett
A/Prof Merrole Cole-Sinclair (until November 2018)
Dr Michael Dray
Dr Jan Kencian (until November 2018)
Dr Nicole Kramer
A/Prof Anthony Landgren
Dr Daman Langguth (since November 2018)
A/Prof Trishe Leong (since November 2018)
A/Prof Bruce Latham
Dr Daniel Owens (since November 2018)
Dr Lynette Waring (since November 2018)
Prof Roger Wilson (until November 2018)

Dividends

The College is a ‘Not for Profit’ organisation and as such does not pay dividends.

State of Affairs

No significant changes in the state of affairs of the College occurred during the financial year.

Short and Long Term Objectives

The College aims to be a self-supporting organisation promoting the study of science and the practice of pathology to ensure that sufficient expert pathology services are available to sustain the practice of medicine and to promote health care in the Australasian region.

Performance Measurement

The College monitors membership and trainee numbers against workforce projections needed to support ongoing demand for pathology services. The College liaises with governments and seeks to implement appropriate strategies to ensure that the workforce of pathologists and scientists is sufficient to meet the projected demand for services. Informal benchmarking of the subscriptions paid by members against subscriptions levied by other specialist medical colleges of a similar size is undertaken. This process has revealed that the College fees continue to be at the lower end of the spectrum.

Environmental Issues

The operations of the College are not subject to significant environmental regulation under the law of the Commonwealth or State.

Member Contribution

Fellows of the College, Honorary Fellows of the College and Fellows of College Faculties would contribute up to $100 each in the event of winding up.
Reports

Incorporation

The College is incorporated and domiciled in NSW, Australia.

New DCEO joins the College

Dr Janet Warner is a Fellow of RCPA with a scope of practice in Chemical Pathology. She holds a PhD in molecular genetics, is a Fellow of the Royal Australian College of General Practitioners (RACGP) and an Associate Fellow of the Royal Australasian College of Medical Administrators (RACMA). She most recently held the position of Director of Pathology and Director of Chemical Pathology at Queensland’s Mater Pathology and was a Senior Lecturer at the University of Queensland.
Board of Directors Meetings

The Board of Directors convened a total of 12 meetings during the year via teleconference and face to face dealing with the many issues presented for decision as well as regular agenda items such as the financial reports, approval of new and updated documents for the College Policy Manual, and approval of candidates for Fellowship and other categories of membership. The Board receives monthly reports from each Board member including financial statements and a report from the CEO.

Major areas covered by the Board over the past year include the new NPAAC supervision document and its implementation. Further progress regarding revalidation requirements in Australia and New Zealand, to be known as Professional Performance Framework PFF in Australia, the lack of progress with the ongoing Medical Benefits Schedule (MBS) Review, and concerns with the MSAC process. The Collection Centre rents issue being addressed by government is also moving slowly, due in part to the disruption caused by the Australian elections. The Board has taken a number of decisions over the year to upgrade security processes for College buildings and systems to ensure the security of information and members.

Board of Education and Assessment (BEA)

Recognition of prior learning standards and formal training programs have been established to certify pathologists as competent to supervise laboratories offering genomic and molecular pathology testing. Professor Edwin Kirk and Professor Anja Ravine, along with discipline-based expert panels, have provided extensive input and assistance with assessment of applicants. The RCPA Continuing Professional Development Program (CPDP) has been updated to meet the standards of the Medical Board of Australia’s new Professional Performance Framework and the Medical Council of New Zealand’s revised revalidation requirements. Changes to the RCPA CPDP will be effective from 2020. The College is on track to meet all AMC/MCNZ accreditation conditions before the four-year review in 2020, following re-accreditation in 2016.

Board of Professional Practice and Quality (BPPQ)

The BPPQ has continued to focus on Government related issues such as the MBS Review, Approved Collection Centre arrangements, Federal Budgets (Pathology related), Pathology Funding and the MSAC Process. BPPQ continues to liaise with the Board on other matters such as pathology workforce issues and revalidation. During the year the chair passed from Dr Lawrie Bott who had completed the maximum permissible time to Dr Daman Langguth. The Committee has an on-going schedule of policy revision and development and frequently makes recommendations for documents and advice to external stakeholders.

Council Committee

Council is tasked with strategic planning for the College and meets annually to consider the issues to be prioritised in the year/s ahead. Council is made up of the Board of Directors (9 members), the State and Regional Chairs (10 members), Advisory committee Chairs (7 members), Faculty Chairs (3 members), Trainee Chair (1 member), Lay committee Chair (1 member), RCPAQAP Chair/Rep (1 member).

Discipline Advisory Committees (ACs)

Another successful year with a number of strategic planning days across disciplines. The volume of documentation for comment received by the College continues as does the involvement of the ACs in providing expertise to assist with responses. Advisory Committees also assist in reviewing existing policy manual documents and in drafting new policies on relevant issues. The contributions of the ACs is of great significance to the major committees and Board of Directors.
Committees

Committees cover all disciplines across subjects of specific interest like Informatics, Cancer Services and Lay Committee. All committees are active and review and produce College policy documents as part of their brief. In 2018 the Board of Directors created a new committee, the Academic Committee, to look at the issues of pathology education (or lack thereof) in the university system and to promote pathology in academia.

Pathology Education Outreach Committee

The Pathology Education Outreach Committee (PEOC) oversees outreach activities in Fiji, Papua New Guinea, Vanuatu, Western Samoa, Tonga, the Solomon Islands, and other Pacific and South-East Asian nations. The main focus of the PEOC is training and education, which complements the pathology service delivery and clinical capacity building that many pathologists generously assist with in developing countries.

State and Regional Committees

State and Regional Chairs and Committees assist with the organisation and running of examinations in their jurisdiction which is of immense value to the College. All State and Regional Chairs are members of the Council Committee which meets annually to consider and direct future strategic planning for the College. Under the guidance of each State/Regional Councillor Annual General Meetings are held often with a speaker and a presentation by the College President. State and Regional Chairs are a valuable resource for Fellows and Trainees alike, opening up lines of communication on local and general issues.

Faculties

Faculty of Science:
The training program continues to develop and is undergoing curriculum expansion. Trainees are progressing through the program with solid performances in the 2019 examinations. New applications via the examination and research pathways are steady.

Faculty of Oral and Maxillofacial Pathology:
The College is maintaining accreditation of its Oral and Maxillofacial Pathology training program in Australia and New Zealand, and Forensic Odontology in Australia. It is hoped that some structural changes to these programs may attract new trainees.

Faculty of Clinical Forensic Medicine:
Two trainees have joined the College’s comprehensive and innovative training program in Clinical Forensic Medicine. The College is pursuing opportunities to accredit new training sites and to recruit more trainees. The Faculty Committee continues to focus on development of guidelines and standards for professional practice and ensuring access to continuing professional development opportunities. The College is preparing a submission to the Medical Board of Australia for recognition of Clinical Forensic Medicine as a new medical specialty.

AMC/MCNZ Accreditation

In 2016, the College was accredited for ten years, subject to annual reports and a comprehensive assessment in 2020. The College has now addressed all recommendations and met most of the conditions arising from the 2016 assessment. This has largely been achieved in advance of the required timeframes, and the College anticipates having all conditions met before the 2020 review. In August 2019, the College report to the AMC will state that the final three conditions are being completed, and most of the others were met substantially in advance of required timeframes.
The RCPA Foundation is a registered charity which is actively involved in fostering research and education within the College Fellowship, offering a number of Grants and Awards each year. The Board of Directors oversees the operation of the RCPA Foundation including fundraising, investment and financial planning and the administration of all grants, awards and scholarships.

Our awards continue to be eagerly sought after with grant and award recipients selected through a competitive application process, which is independently assessed by a Grants subcommittee. The written reports from recipients after completion are particularly heartening and offer insight into the knowledge and experience gained, confirming the value of this work to the individuals and the profession as a whole.
The scientific journal *Pathology* continues to represent the College successfully both within Australia and internationally. The impact factor increased again in 2018 to 3.163 and the number and quality of submissions is continually improving.

Another well received theme issue was published in early 2019 on lipids and cardiovascular disease and the RCPA *Pathology* Article of the Year Award was presented again at Pathology Update 2019. The journal publisher, Elsevier, promotes the profile of the journal with timely publication, online visibility, and successful marketing.

The Editor, Associate Editors and Editorial Board provide their time and expertise to maintain the quality and relevance of *Pathology*. 
The College continues to communicate via multiple pathways and is always open to Fellows’ input and comments. The main vehicles for communication are:

Direct:
The College may at times communicate with Fellows in regard to contact details, CPD, subscriptions or other matters. The College will not pass on your details to external requestors without asking you first. If you wish to contact the College on any matter you can phone: 61-2 8356 5858, email: rcpa@rcpa.edu.au, post: RCPA 207 Albion Street, Surry Hills NSW 2010.

Website:
www.rcpa.edu.au
A vast amount of information is available to all users, however for full access Fellows need to log in. Log in issues can be resolved by contacting the College. One reason for log in problems is unpaid subscriptions. If in arrears for 6 months, the system automatically locks access to the database and all publications.

Committees:
Discipline and other committees are consulted on documents and issues requiring feedback almost entirely via email.

College events/courses:
Pathology Update, and the many courses across the year (see events section in this report) offer education and interaction and are listed on the website and in the newsletter.

AGM:
The Annual General Meeting of the College reviews the previous year, and Annual General Meetings for the states and regions do the same in each area as well as giving Fellows the opportunity to come together. The College AGM is the forum for the annual financial report and the election of the new members to the Board of Directors. In line with current legislation it must take place within five months of the end of the financial year.

Surveys:
From time to time the College conducts surveys of Fellows. The survey may require a simple Survey Monkey response or could involve external consultants. Surveys offer the opportunity for members to have a say on issues that matter.

Social media:
The College is active across several social media platforms. Connect with us:

- The Royal College of Pathologists of Australasia RCPA
- @PathologyRCPA
- @the.rcpa
- The Royal College of Pathologists of Australasia
Pathology Today

Produced fortnightly, *Pathology Today* provides the latest in College news and includes items of news from third parties as well as regular segments on forthcoming/past events and job vacancies. It is the main vehicle to advertise Calls for Nominations and to invite applications for various College/external activities.

Pathology

The scientific journal is delighted that the approval rating continues to climb. The journal has gone from hard copy only to a majority uptake as an online product in just a few years. Hard copies are available but are more costly, take longer to arrive and delivery addresses are not always accurate, as evidenced by the high return rate.

Annual Report

Produced in hard copy for all RCPA AGM attendees, the Annual Report is available (current and past issues) on the College website in an easy to access flip page version.

ePathway

A monthly eNewsletter sent to a large external audience including government and department contacts, stakeholders and Fellows. Designed to cover current issues, specific discipline areas and generally inform on the profession and those who practice in it.

Policy Manual

The College maintains well over 300 documents which cover a range of categories including Guidelines, Grants and Awards, Position Statements, Policies, Terms of Reference and Roles and Responsibilities. It is a living manual in the sense that documents are reviewed and updated every four years (or sooner if required), new documents created as needed and those no longer needed are rescinded. All Policy Manual documents are available via member log in to the website. Updates are approved by the Board of Directors and advised each month via *Pathology Today*.
MONASH UNIVERSITY MEDICAL STUDENT SOCIETY – CAREERS NIGHT (MUMUS)
Friday 27 July 2018, Melbourne VIC

Dr Kay Weng Choy represented the College at the MUMUS Careers night and was kept busy as many students were enthusiastic about pathology as a future career. A number commented they were not aware pathology was much more than just anatomical pathology. Common enquiries included the pathways/prerequisites to pathology training, commitments during training and after completion, assessments/examinations. A successful night as many expressed interest in sitting the RCPA basic pathological sciences examination.

RCPA EVENTS

Courses held 1 July 2018 – 30 June 2019

AMSA NATIONAL CONVENTION
PERTH CAREERS EXPO
Friday 6 July 2018, Perth Convention Centre, WA

The Annual AMSA Conference attracted 1000+ student attendees with many visiting the Careers Expo on Friday 6 July. The RCPA booth had a prime location and was kept busy throughout the day by many students showing interest in Pathology as a future career. Dr Marcus Dabner, Dr Clive Cooke and Dr Alanah Buck supported the College providing invaluable advice to students.

L to R Dr Kay-Weng Choy/Trainee and Jonathan Wong / MUMUS Representative

R to L Dr Clive Cook, Dr Kathy Robinson, Dr Alanah Buck and Dr Dan Moss
RCPA Events

**FORENSIC INTERIM MEETING**  
Friday 24 – Sunday 26 August 2018, Vibe Hotel, Darwin NT

A mix of attendees included science and medical students, pathology trainees and Fellows of the College from across Forensic Pathology, Clinical Forensic Medicine and the Faculty of Oral and Maxillofacial Pathology. Presentations were diverse, aimed to focus on locally relevant topics, including environmental deaths in the Northern Territory, crocodile attacks, Meloidosis and heat stress. Under the guidance of course convenor A/Prof Neil Langlois, a number of newer members of the College excellently delivered their first contribution to a Forensic Pathology Interim meeting.

![Delegates and Scientific Convenor A/Prof Neil Langlois](image)

**NZ ASM - WILD ABOUT WELLINGTON**  
Friday 21 - Sunday 23 September 2018, Rydges Hotel, Wellington New Zealand

The New Zealand Annual Scientific Meeting featured Dr Matt Quick from Little Rock, Arkansas who delivered brilliant presentations to delegates. With two scientific programs running (Anatomical and Chemical Pathology) guided by course convenor Dr Vladimir Osipov, the meeting kept delegates busy and energized. The social program gave everyone a chance to network and exchange ideas. Dr Lydia Hill won IGENZ Best Trainee Poster and Dr Claire French Best Oral Presentation. Dr Peter Bethwaite gave an engaging AB Pearson Memorial Oration linking his love of classical music and fascination with patterns as his motivation to specialise in Anatomical Pathology.

![L to R - Dr Lydia Hill IGENZ Best Trainee Poster & Dr Claire French Best Oral Presentation](image)
RCPA Events

AIDA CONFERENCE (AUSTRALIAN INDIGENOUS DOCTORS’ ASSOCIATION)
Thursday 26 - Saturday 28 September 2018, Crown Convention Centre, Perth WA

The College exhibited over three days of the conference to promote the profession. The booth was very busy with great interest in all disciplines particularly Forensic, Anatomical and Haematology. College volunteers President Dr Bruce Latham, Dr Michael Page and Dr Ben Armstrong presented the Growing our Fellows Workshop and answered questions from interested Medical Students. The social program was busy with a Welcome to Country on the banks of the Swan River and Gala Night celebration for new graduates and fellows.

CMV INFECTIONS WORKSHOP
Saturday 13 October 2018, RCPA Alan BP Ng Education Centre Sydney NSW

The inaugural RCPA CMV Infections Seminar looked at the laboratory and clinical aspects of managing this difficult infection in transplant patients, pregnant women and neonates. Convened by Dr Raymond Chan, attendees included scientists, RCPA Fellows and trainees in microbiology, infectious diseases and haematology. All engaged enthusiastically in the case-based discussions about CMV infection in solid organ transplant and haematological patients. Attendees heard the most up to the minute data on CMV drug resistance and newer drugs for management of CMV.
RCPA Events

ANATOMICAL PATHOLOGY AND LABORATORY SKILLS WORKSHOP (APLS 2018)
Thursday 18 – Saturday 21 October 2018, Ballarat VIC

Convened by Dr Simon Nazaretian the 33 delegates included anatomical pathology and forensic pathology registrars and hospital medical officers from Australia, New Zealand and Saudi Arabia. The workshop assists with Part 1 exam preparation and provides a relaxed environment for trainees with an opportunity to develop practical skills in a variety of laboratory techniques. Lecturers and practical demonstrators included anatomical pathologists and scientists from 9 different laboratories in Victoria. “The course is amazing... a great course for pre-Part 1 candidates and I would highly recommend it to all future candidates. It contains relevant information that is presented well. The practical workshop was invaluable.” – Delegate comment

APLS 2019 Delegates and Speakers

TRENDS IN SURGICAL PATHOLOGY
Wednesday 24 October 2018, Concord Hospital, Sydney

Another successful event with some excellent presentations from impressive young trainees on a wide variety of topics. Special guest speaker was Dr Ron Newland (head of AP at Concord Hospital until he retired in 2001) who took a trip down memory lane in his talk on the history of the ‘Trends in Surgical Pathology’ meeting which was founded in 1972 by Dr Theo Constance. Ron attended the first Trends meeting and was a frequent presenter for over 30 years. Ron highlighted the transformational changes that have taken place over the life of Trends “the recognition of many new disease entities, the revision of disease classifications, the introduction of powerful new diagnostic tools and the increasing requirement for pathology reports to go well beyond simply providing a diagnosis”.

Karen Mackenney, Dr Ron Newland and Dr Louise Hughes (Course Convenor)
SHORT COURSE IN POST MORTEM FORENSIC TOXICOLOGY
Thursday 25 - Saturday 27 October 2018, RCPA Alan BP Ng Education Centre, Sydney

Talks were presented by Professor Olaf Drummer; Dr Dimitri Gerostamoulos; Ms Miriam Grist of Forensic Sciences Services Tasmania; and Dr Don Ritchey the Course Convenor. Discussions ensued on the complexities of post mortem forensic toxicology interpretation with an emphasis on case reports and commonly encountered drugs and poisons. There were 20 students from diverse backgrounds including clinical forensic medicine, pathology trainees and consultants and bench scientists from toxicology laboratories around Australia.

MANAGEMENT IN CLINICAL GOVERNANCE OF MEDICAL LABORATORIES
Friday 16 - Saturday 17 November 2018, RCPA Alan BP Ng Education Centre, Sydney

Previously known as Management in Pathology the Management and Clinical Governance of Medical Laboratories course offered pathologists and senior scientists a framework for managing laboratories. There was a strong emphasis on clinical governance and risk management to help prepare for the new NPAAC Supervision Requirements. Topics covered insights and experiences in current issues facing pathology, introduction to management in pathology, integrated clinical and corporate management, clinical quality management activities, strategic development and service planning in public/private pathology, clinical privilege and scope of practice, incident management, evidence based medicine, introduction to clinical governance and risk management in pathology, the role of the College Fellow in relation to laboratory accreditation, and as a NATA RCPA assessor.
RCPA Events

PATHOLOGY INFORMATICS SEMINAR
Monday 19 - Tuesday 20 November 2018, RCPA Alan BP Ng Education Centre, Sydney

The Chairs of the PITUS 18-20 Steering Committee and each of the PITUS working groups were among the twenty speakers. Day 1 focused on pathology informatics including updates on the Pathology Information, Terminology and Units Standardisation (PITUS) 18-20 Project, Standards for Pathology Informatics in Australia (SPIA), My Health Record (MyHR), Fast Healthcare Interoperability Resources (FHIR), Structured Reporting of Cancer Protocols (SPRC), report formatting and current industry issues. Day 2 provided an overview of Pathology messaging, SNOMED-CT and LOINC terminology, and advanced concepts for pathology informatics regarding the linking of SNOMED-CT and LOINC standards with information databases plus privacy and data issues. Course convenor A/Prof Ken Sikaris organised a brilliant collective of minds and all speakers delivered exceptional presentations. The RCPA Pathology Informatics Course is a biennial RCPA educational activity (next seminar 2020).

UNIVERSITY OF QLD (UQ) MEDICAL CAREERS CONFERENCE
Saturday 2 March 2019

Thank you to Dr Sarah Cherian and the volunteers who manned the College Booth; and Dr Michael Harrison; General Pathologist and Past President of the Royal College of Pathologists of Australasia, for presenting on behalf of the Pathology Discipline.

PMCWA MEDICAL CAREERS EXPO PERTH
Wednesday 13 March 2019
University Club of WA, Nedlands

Thank you to our volunteers: Prof John Burnett, Dr Marcus Dabner, Dr Michael Page and Dr Sara Hall.

JMO CAREERS INFORMATION NIGHT
Monday 18 March 2019
Warrnambool Base Hospital

Thank you, Dr David Blaxland, for your time and for representing the field of Pathology.
RCPA Events

ADELAIDE SMALL BIOPSY COURSE 2019
Saturday 23 – Sunday 24 March 2019, AHMS University of Adelaide, SA

The course boasted a distinguished faculty of both local and interstate speakers with a wealth of experience. Speakers were generous with their cases, time and knowledge, and their contributions appreciated by all. There were 66 Trainees who attended, and feedback has been generally positive. Digital cases were available on line for review at least 8 weeks prior to the course, providing registrants a treasure trove with which to test their knowledge prior to the upcoming exam.

L to R: Dr Catriona Brennan, Dr Esther Quick and Dr Nick Manton

MICROBIOLOGY MOLECULAR WORKSHOP 2019
Friday 5 - Saturday 6 April 2019, RCPA Alan BP Ng Education Centre, Surry Hills NSW

This was the 3rd Microbiology Molecular Workshop and was a joint program between the RCPA and RCPAQAP. Convened by Dr Robert Norton it covered a broad area of diagnostic molecular microbiology but centred on the application of sequencing for this field. Leading Australian scientists and pathologists in the field, presented on the topics. The workshop was well attended by microbiology trainees and scientists with a full house of 64 delegates.

Pictured: Dr Jenny Robson, Dr Robert Norton, Dr Neisha Jeoffreys, Dr Darren Jardine, Dr Amy Jennison, and A/Prof Christopher McIver
RCPA Events

TUMSS TASMANIAN UNIVERSITY MEDICAL STUDENTS’ SOCIETY CAREERS NIGHT
Wednesday 17 April 2019

Dr Sam Hitchins, a member of the Tasmanian State Committee and haematologist; and Dr Helen Harris, Anatomical Pathology Fellow, volunteered to assist with the booth and present on behalf of the College and Pathology.

ICPMR IMMUNOPATHOLOGY COURSE 2019
Wednesday 8 – Friday 10 May 2019,
The Westmead Institute, NSW
Course convenors: A/Prof David Brown, Dr Ming-Wei Lin and Dr Melanie Wong

As with previous courses, an excellent range of local, interstate and international speakers discussed subjects relevant to the modern practice of Immunopathology. Although primarily aimed at trainees, the course content provided opportunities for all attendees to learn and/or update in a relaxed and open forum, with encouragement to comment and ask questions. The course convenors A/Prof David Brown, Dr Ming-Wei Lin and Dr Melanie Wong thanked all the speakers for their time and valuable contributions.

AMA VICTORIA MEDICAL CAREERS EXPO
Saturday 11 May 2019, MCEC, South Bank VIC

The AMA careers day provided a successful opportunity to highlight the many and varied careers that are possible in pathology. There was a lot of interest at the RCPA booth, keeping our volunteers busy the whole time. This year there was a particular interest in Forensic Pathology and overall most students were very interested in how pathology is intimately related to a number of other specialities. Thank you to our volunteer’s Dr Albert Yin, Dr Diana Moir and Dr Niles Nelson.

MEDSOC UNSW  Wednesday 8 May 2019
Thank you to volunteers Dr Andrew Parker and Dr Catriona McKenzie for attending.

RECENT ADVANCES PATHOLOGY LECTURE AND TOO HARD SLIDE SHOW 2019
6 March – 5 June 2019

The 2019 Recent Advances Pathology Lecture and Too Hard Slide Show took a successful change in format. The sessions were almost all workshops that focused on key areas of histopathology and cytology. Specialities that are not seen at all institutes (such as liver, renal and melanocytic pathology) were chosen and presented by experts in the field. Part 1 and 2 practice slide exams for exam candidates were also undertaken, with a discussion session open to all registrants.
PATkology update 2019 – The Power of Personalised Pathology

Friday 22 – Sunday 24 February 2019
Melbourne Convention and Exhibition Centre, South Wharf, Melbourne VIC

A key annual scientific educational meeting, it is the only conference of its kind in Australasia bringing together all pathology professionals from all disciplines of pathology. Pathology Update 2019 brought internationally renowned pathologists to Melbourne to present in their fields allowing delegates the opportunity to hear presenters of high calibre, especially useful for trainees and pathologists from the smaller disciplines.

The event is a complex 3-day conference with seven core discipline program streams, three combined sessions, workshops, 146 local speakers, 11 international speakers and over 50 program chairs. The gathering includes pathologists, trainees, scientists, administrators and healthcare workers from Australasia and other parts of the world. There were 1370 delegates from 18 different countries covering the disciplines of Anatomical Pathology, Haematology, Chemical Pathology, Immunopathology, Microbiology, Forensic, Genetic, General and Paediatric Pathology along with the three faculties of College. Ongoing education helps ensure current best practice and fulfils professional requirements for continual practice improvement through the CPDP program of the College. Scientific Program committees work years in advance to ensure each discipline has their own tailored scientific program plus some combined sessions. All delegates came together each day for plenary sessions (David Rothfield Memorial Oration, Eva Raik Plenary and Innovations) and Masterclasses were also held. Social events and the New Fellows and Awards ceremony offer an additional flavour to Pathology Update as does the opportunity to network and catch up with colleagues.

Prof Brett Delahunt presented a Masterclass on the topic of “The Publication Game. How to write and review a paper: what an editor wants.” It was attended by over 200 delegates, a mix of trainees, supervisors, and experienced pathologists who review and write articles for the RCPA journal Pathology and other journals. He gave practical tips and a strong warning about the increasing problem of predatory journals. Feedback indicated the advice was helpful for preparing scientific articles and case reports for publication, and improving reviewer reports.

Dr Tim Sharp, aka “Dr Happy” presented a dynamic Sunday morning Masterclass about an issue affecting many pathologists across all disciplines - stress, its effects on the body and how to avoid burnout. His practical explanations and suggestions clearly engaged the audience, with an active Q&A session and a concluding video that reminded everyone that small efforts can make a big difference.
Special Events

Chatting between sessions

Medical Students breakfast well attended

Ready for a session

Presentation underway

Developing communities attendees

Closing drinks event
Special Events

Welcome cocktail party

Events Manager and Prof D Chan (USA)

RCPA Board of Directors

New fellows prepare to enter the hall

RCPA Fellow Dr Adams leads the anthem

President presents a Faculty Fellowship certificate
RCPA VISITING LECTURER TO OVERSEAS
Prof Jane Dahlstrom, Visiting Lecturer 2018.

Jane delivered a Plenary Lecture “Cystic Lesions of the Jaw” to the Academy of Medicine during her visit to Singapore. “Errors made and Lessons learnt in Histopathology” was the title of Prof Dahlstrom’s main address at the ASM of the Singapore Society of Pathology. Her visit included lectures and symposia at Singapore General Hospital to an audience of primarily pathologists and trainees, but also interested local researchers and clinicians. Dr Inny Busmanis, RCPA Councillor for Singapore, organised the events with the assistance of local pathologists and clinicians. Prof Dahlstrom also visited Malaysia and Hong Kong.
CEO CELEBRATES 20 YEARS AT RCPA

RCPA Chief Executive Officer Dr Debra Graves was honoured at a special event held at the College in February 2019 to celebrate, 20 years to the day, her exceptional service to the College. A number of people, including past presidents and past staff as well as current Fellows, staff members and close friends attended the lively event. A/Prof Peter Stewart, a member of the original panel who appointed Debra spoke of his memories of the original interview.

It has been an interesting journey as Debra herself pointed out, one which took the College from a few metal filing cabinets to a modern up to date technologically advanced business. Staff numbers have gone from 9 to 44 and the premises have been revamped to accommodate them and reflect the changing needs of the College. Debra’s open-door policy, quick mind and ability to deal with matters quickly and decisively have led the way for the growth.

Along her journey there have been 11 Presidents and six of them were in attendance for the party, a mark of respect for her wonderful guidance over the years. There was a presentation of a photographic book covering her 20 years and at Pathology Update 2019 a special cake was presented to mark the 20 years.
FELLOWSHIPS AWARDED

1 July 2018 - 30 June 2019

Fellow FRCPA

Dr Benjamin Allanson
Dr Melanie Archer
Dr Aliya Azlan
Dr Teresa Bailey
Dr Angela Bayly
Dr Puja Bhattacharyya
Dr Nicholas Bingham
Dr Matthew Blakiston
Dr Maxim Bloomfield
Dr Yvonne Brennan
Dr Elsie Burger
Dr Liesl Butler
Dr Ashlea Campbell
Dr Simon Carrivick
Dr Joshua Casan
Dr Khai Chai
Dr Jonathan Chambers
Dr Claire Chambers
Dr Kah Lok Chan
Dr Cheng Yee Chan
Dr Khin Chaw
Dr Tony Chen
Dr Xin Min Cheng
Dr Ka Chew
Dr Nicole Chien
Dr Yee-Shuen Chong
Dr Kay Weng Choy
Dr Gerard Chu
Dr Chong Chua
Dr Joseph Clarey
Dr Lisa Clarke
Dr Andrew Colebatch
Dr Lily Dang
Dr Tony Dill
Dr Lorraine Du Toit-Prinsloo

Dr Anna Eastman
Dr Hannah Elstub
Dr Fionnuala Fagan
Dr Forough Foroughi
Dr Kathryn Forwood
Dr Celia Green
Dr Maria Grobler
Dr Melissa Hancock
Dr Joshua Hopp
Dr Dona Horadagoda
Dr Julia Howard
Dr Vanya Hristova
Dr Carly Hughes
Dr Chung Yee Hui
Dr Andrew Hutchison
Dr Tony Huynh
Dr Shah Inam
Dr Tishya Indran
Dr Prasad Jayaratne
Dr Jocelyn Jiang
Dr Annie Jo
Dr Maansi Joshi
Dr Lauren Kalinowski
Dr Charithani Keragala
Dr Elizabeth Klinken
Dr Fong Koh
Dr Nicholas Koh
Dr Masa Lasica
Dr Vivienne Lea
Dr Gar-Hing Lee
Dr Daphne Loh
Dr Theresa Ly
Dr Victoria Madigan
Dr Roslyn Malley
Dr Annalise Martin
Fellowships Awarded

Dr Madeleine McKinley
Dr Heshani Mediwake
Dr Diana Moir
Dr Yingting Mok
Dr Ali Mokhtarpour
Dr Olga Motorna
Dr Mudiwa Muronda
Dr Harini Narayanappa
Dr David New
Dr Teng Fong Ng
Dr Wai Yan Ng
Dr Sara Ng
Dr Ann Niap
Dr Danielle Oh
Dr David Paton
Dr Shadi Pirasteh
Dr Veronica Playle
Dr Amy Power
Dr Ashvind Prabahran
Dr Phillippa Pucar
Dr Indu Raman
Dr Samuel Roberts-Thomson
Dr Laveniya Satgunaseelan
Dr Adam Scarlett
Dr Charles Shuttleworth
Dr Amandeep Singh
Dr Eranga Siriwera
Dr Gwyneth Soon
Dr Hannah Stevens

Dr Vichitra Sukumaran
Dr Yi Sun
Dr Adam Swalling
Dr Sze Pei Tan
Dr Catherine Tang
Dr Mark Taylor
Dr Nisha Thiagarajah
Dr Esther Ting
Dr Oliver Treacy
Dr Nermina Vagaja
Dr Rebecca Walsh
Dr Jennifer Wang
Dr Brendan Wisniowski
Dr Stephen Wong
Dr Soon Boon Wong
Dr Angelina Yong
Dr Melissa Yssel
Dr Hiu Lam Yuen
Dr Liqing Zhuang

Fellow Faculty of Science
A/Prof Phillip Clark
Prof Maria Carola Garcia De Vinuesa
A/Prof Christine Hemmings
Dr Wayne Rankin
Dr Richie Soong
Dr Simone Van Es
Dr Anja Werno
AWARDS PRESENTED 2019

Honorary Fellowship
Dr Elaine Jaffe

Distinguished Fellow Award
A/Prof David Ellis
Dr Colin Goldschmidt

Meritorious Service Award
A/Prof Christine Hemmings

Konrad Muller Outstanding Teaching Award
Dr Sean Chang (Pathologist)
Dr Christine Bundell (Scientist)

RCPA Foundation Mike and Carole Ralston Travelling Fellowship
Dr Kylee Maclachlan

RCPA Foundation Kanematsu/Novo Nordisk Research Award
Dr Ibrahim Tohidi-Esfahani

RCPA Foundation Postgraduate Research Fellowship
Dr Lavenyia Satgunaseelan
Dr Gerard Chu
Dr Andrew Henderson

RCPA Journal Pathology Article of the Year 2017
Dr Owen Dent
A/Prof Ron Newland

The Neil Prentice Memorial Prize
Dr Sarah Cuddihy

The Eddie Hirst Memorial Prize
Dr Sophie Hale

The Barbara Williams Cytopathology Memorial Prize
Dr Harini Narayanappa

DS Nelson Trainee Prize
Dr Timothy Cheng

Board of Education and Assessment Trainee Poster Prize
Dr Ian Gossiep

RCPA QAP Pty Ltd Oral Presentation Prize
Dr Joel Smith

RCPA QAP Pty Ltd Poster Presentation Prize
Dr Michael Findlay

Roche Scientific Poster Display Prizes
Anatomical Pathology
Mr Hyun Joon Kim

Chemical Pathology
Dr Chi Sing Leo Lam

Forensic Pathology
Dr Sinead McCarthy

Genetic Pathology
Dr Helena Jang

Haematology
Dr Serena Ekman

Immunopathology
Dr Brittany Stevenson

Microbiology
Dr Belinda Lin
Dr Bruce Latham  
**President**  
*BMed Sci (Hons), MBBS, FRCPA*

Bruce Latham is a graduate of the University of Western Australia. He carried out his anatomical pathology training predominantly at Royal Perth Hospital and was admitted to Fellowship in 1995. Bruce has worked as an Anatomical Pathologist in both the public and private sector, and is currently an Anatomical Pathologist with PathWest at Fiona Stanley Hospital where he has a diagnostic and research interest in breast and pulmonary pathology. He is a member of the RCPAQAP Anatomical Pathology General Module Committee and is an Adjunct Associate Professor at Notre Dame University. He was previously RCPA State Councillor Western Australia and a member of the Anatomical Pathology Advisory Committee.

Dr Michael Dray  
**Vice President**  
*MChB (Otago), DCH, Dip Obst, FRCPA*

Michael Dray is a Consultant Histopathologist based at Waikato Hospital where he is now the Clinical Unit Leader of the Waikato District Laboratory Services. He gained his medical degree from the University of Otago. His initial medical career saw him in General Practice for several years prior to training in Anatomical Pathology in Sydney, NSW for 5 years before returning to New Zealand in 2006. He spent 6 years working at Middlemore Hospital, South Auckland, before moving to his current position. He is also a Senior Lecturer at the University of Auckland being an active member of the Bone & Joint Research Group, and a Coronial Pathologist. He has served on a number of College committees and is an examiner in AP. He was Chair of the RCPA New Zealand Committee from 2011-2017 and on the Board of Directors in that capacity.

Dr Nicole Kramer  
**Vice President, New Zealand**  
*MChB FRCPA*

Nicole Kramer is a Consultant Anatomical Pathologist at North Shore Hospital, Auckland. She graduated from the University of Auckland and completed her Pathology Fellowship in 2011, training in in Auckland and the Waikato. She has been a member of the National Bowel Cancer Working Group and the Lead Pathologist for the National Bowel Screening Pilot. She is current Chair of the RCPA NZ Committee of Pathologists, a member of the National Bowel Screening Advisory Group and is an active member of the NZ Neuroendocrine Tumour Research Group.
A/Prof Trishe Leong
Secretary/Treasurer
MBBS (Hons) FRCPA MBA (Exec) AFRACMA PGDipMDPath

Trishe Leong is the Medical Director of Pathology and Director of Pathology at Austin Health, Melbourne. She received her undergraduate medical degree from the University of Adelaide and trained in Anatomical Pathology in Melbourne, being admitted to Fellowship in 2006. Following this she worked at Monash Medical Centre and the Victorian Cytology Service, where she was Deputy Managing Pathologist, before joining the Austin in 2010. She previously served from 2015-2018 as the Honorary Treasurer of the Australasian Division of the International Academy of Pathologists, followed by a term as Divisional Vice President, and has been a member of the Steering Committee of the International Collaboration on Cancer Reporting and the Deputy Chair of the Cytopathology Advisory Committee for the College.

Dr Tony Landgren
Chair, Board of Education and Assessment
Chair, Board RCPAQAP Pty Ltd
MBBS LLB FRCPA FACLM AFACHSE MRACMA FAICD
Barrister & Solicitor Supreme Court of Victoria

Tony Landgren is a graduate in Medicine and Law from the University of Melbourne. He trained in Anatomical and Forensic Pathology in Victoria and was admitted to Fellowship in 1990. Tony has worked as a pathologist and administrator in private and public practice in Australia, New Zealand, Malaysia, Singapore and the United States. He is Director of the Department of Anatomical Pathology at the Royal Melbourne Hospital and Medical Director/Chief Pathologist at Australian Clinical Labs. His legal practice specialises in Commercial, Insurance and Biotechnology Law. He holds academic appointments at the University of Melbourne.

Dr Daman Langguth
Chair, Board of Professional Practice and Quality
BHb, MBChB, FRACP, FRCPA, AAICD

Dr Daman Langguth is a Consultant Immunopathologist at Sullivan Nicolaides Pathology and Clinical Immunologist at the Wesley Hospital, Brisbane. He has been a member of many College committees and at present is Chair of the Board of Profession Practice and Quality since 2018. He is Chair of Partners at Sullivan Nicolaides Pathology and chairs the data request committee. He is also a member of the Sonic Healthcare Australia credentialing committee. His research interests include laboratory informatics, the immunology of ECMO, and ANCA vasculitis.
Dr Daniel Owens  
**Council Representative for States and Regions**  
*BMsc, MBBS (hons), FRCPA*

Daniel Owens is a graduate of the University of Tasmania. He trained in Clinical and Laboratory Haematology at St Bartholomew’s Hospital, London and the Prince of Wales Hospital, Sydney. He is a Consultant Haematologist at Hobart Pathology and the Royal Hobart Hospital. Daniel is the RCPA State Councillor for Tasmania and is a member of the RCPA Board of Professional Practice and Quality (BPPQ) and the RCPA Haematology Advisory Committee. He is an RCPA Examiner for Haematology.

---

Dr Lynette Waring  
**Council Representative, Advisory Committees**  
*BSc MBBS FRCPA*

Dr Waring graduated from the University of Western Australia, after several years of paediatric training, then gained her FRCPA in Medical Microbiology in 1995. She completed an Infectious Diseases Fellowship at Stanford University Medical School, California. She has worked as a Medical Microbiologist in both the private and public sectors and is currently the Director of Microbiology and Immunoserology at Melbourne Pathology. She has also worked as the clinical lead in Biopharma companies in California, USA, including Chiron, Novartis and Roche Molecular Diagnostics. She has a strong interest in education and is active in the RCPA. She has previously served for 6 years on the RCPA Microbiology Advisory Committee, is an examiner, the joint Network Coordinator for Training in Victoria, current Chair of the RCPA Microbiology Advisory Committee, a member of the RACP Infectious Diseases Joint Training Committee and is overall Chair of the RCPA Advisory Committees.

---

Prof John Burnett  
**Council Representative, General**  
*MBA MD PhD FRCPA FFSc FACB FAHA FCSANZ*

John Burnett received his undergraduate medical education at the University of Otago and was admitted to Fellowship of the Royal College of Pathologists of Australasia (Chemical Pathology) in 1992. He was a Fellow in Medical Biochemistry at the Robarts Research Institute and University of Western Ontario and recipient of a Heart and Stroke Foundation of Canada Research Fellowship. He was awarded a PhD in Biochemistry from the University of Western Ontario in 1998 and the higher degree of MD from the University of Otago in 2004. He moved to Australia in 1999 and is a Consultant Chemical Pathologist in the Department of Clinical Biochemistry at PathWest Royal Perth Hospital and Fiona Stanley Hospital Network, and Clinical Professor in the School of Medicine at the University of Western Australia. He was WA State Councillor from 2006-2010 and is currently Chief Examiner in Chemical Pathology, Chair of the Chemical Pathology Advisory Committee, and Senior Associate Editor of Pathology.
During the financial year 1 July 2018 to 30 June 2019 thirteen (13) meetings of the Board of Directors took place.

<table>
<thead>
<tr>
<th>Alphabetical list of Directors</th>
<th>Directors Meetings</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Eligible to attend</td>
</tr>
<tr>
<td>Dr Lawrence Bott</td>
<td>6</td>
</tr>
<tr>
<td>Prof John Burnett</td>
<td>13</td>
</tr>
<tr>
<td>A/Prof Merrole Cole-Sinclair</td>
<td>6</td>
</tr>
<tr>
<td>Dr Michael Dray</td>
<td>13</td>
</tr>
<tr>
<td>Dr Janet Kencian</td>
<td>6</td>
</tr>
<tr>
<td>Dr Nicole Kramer</td>
<td>13</td>
</tr>
<tr>
<td>Prof Anthony Landgren</td>
<td>13</td>
</tr>
<tr>
<td>Dr Daman Langguth</td>
<td>7</td>
</tr>
<tr>
<td>Dr Bruce Latham</td>
<td>13</td>
</tr>
<tr>
<td>A/Prof Trishe Leong</td>
<td>7</td>
</tr>
<tr>
<td>Dr Daniel Owens</td>
<td>7</td>
</tr>
<tr>
<td>Dr Lynette Waring</td>
<td>7</td>
</tr>
<tr>
<td>Prof Roger Wilson</td>
<td>6</td>
</tr>
</tbody>
</table>
From 1 July 2018 to 30 June 2019 the College learnt of the passing of the following members.

Dr David John Astill
Dr Leon Platt Bignold
Dr John Gerald Clement
Prof David John Davies
Prof Douglas Warrington Henderson, AO
Dr Rees Hollier Jones
Dr David Ewen Leslie
Prof Timothy John Lyons
Dr Michael Patrick Metz
Prof Howard Morris
Dr John Joseph Sullivan
Ms Jill Russyll Tate

The College is not always made aware of the passing of Fellows and apologies for any inadvertent omissions.
Dr David St John Astill
Late of South Australia 1960-2019

Dr David St John Astill had a broad experience in diagnostic pathology laboratories having worked in them since 1978 in a range of roles from TGO-0 through to Head of Department, Anatomical Pathology and Site Clinical Director at Flinders Medical Centre. Initially a Technical Officer in Microbiology at Gribbles Pathology he moved to IMVS in 1985. He obtained a Diploma in Medical Laboratory Science then a first class honours degree in Microbiology & Immunology (Adelaide University). In 1996 he completed a PhD in Molecular & Biophysics (Adelaide University) on the major chloride permeation pathway in skeletal muscle. He then entered the postgraduate medical program at Flinders University, graduating in 1999. He had two years in clinical medicine before his career took him back to the laboratory where he undertook specialist training in anatomical pathology and obtained RCPA Fellowship in 2006.

An Anatomical Pathologist at Flinders Medical Centre for the last 12 years he was appointed Head of Department in 2014 and then Site Clinical Director. His external roles during that time included Assistant Chief Examiner in Anatomical Pathology for RCPA. He developed expertise in many areas of Anatomical Pathology, including dermatopathology, haematopathology and liver pathology. Over the years, he made an immense and well-appreciated contribution to the Dermatology, Head and Neck and Breast/Endocrine units at Flinders Medical Centre.

Outside of work his passions included riding motorcycles. An excellent communicator with a sharp wit and an excellent mimic his repartee and good humour will be sorely missed. Colleagues at Flinders Medical Centre include his wife Liz. All were devasted by the sudden loss of such a valued colleague and friend.

Dr Leon Platt Bignold
Late of South Australia 1947–2018

A Fellow of the College since 1980, with a scope of practice in Anatomical Pathology Leon graduated in Medicine from the University of Western Australia, and had post-graduate qualifications in internal medicine, experimental pathology and diagnostic histopathology. From the 1980s on he practiced and taught general and diagnostic histopathology at the University of Adelaide and the South Australian state government pathology service (SA Pathology, formerly Institute of Medical and Veterinary Science).


With colleagues, he published a study of the origins of tumour pathology and a volume on the history of medicine: “Virchow’s Eulogies” Birkhäuser, Basel, (2008). He taught many undergraduate and postgraduate students over the years and had the ability to break down even the most complex topics in a way that made them easy to understand.
Obituaries

Dr John Gerald Clement
Late of Victoria 1948–2018

A Fellow of the Faculty of Oral and Maxillofacial Pathology in Odontology, Dr Clement also served on the Faculty Committee. A man of many interests and talents, his theme of valuing others and practising fairness ran throughout his life. UK born he was the first of his family to attend university and chose, for his dental degree, University College London as it encouraged diversity. He completed a PhD in 1986, researching the formation of shark cartilage and went on to become internationally recognised in comparative and human anatomy.

Emigrating to Australia in 1989 for a role as senior lecturer in oral anatomy at the University of Melbourne he established the graduate diploma course in forensic odontology, a first in Australia to give practicing dentists a formal qualification in the field. John collaborated with VIFM where he established a collection of experimental bone material which achieved international renown and worldwide collaborations. Over his long career he identified thousands of disaster victims, from events like the oil platform disaster in the North Sea (1988), Port Arthur massacre (1996), Silk Air disaster (1997), Indian Ocean tsunami (2004), Black Saturday bushfires in Victoria (2009), and mass graves in Bosnia.

John was involved in establishing several scientific and professional organisations that examined the interaction between dentistry and the law. From 1999 he held the inaugural chair for forensic odontology at the University of Melbourne and was former deputy head of the dental school. His research ranged from forensics and victim identification, to anthropology, human rights and hard tissue biology. A passionate and considerate mentor and teacher he tried to support promising researchers. He advocated for women and those from overseas at a time when they were often excluded from opportunities granted to others.

His vast network of friends and collaborators fortified his lifelong curiosity about the world. A great traveller, he had close friendships with associates in Japan, first at the Tsurumi University School of Dental Medicine (TUSDM) and the National Research Institute of Police Science (NRIPS). An Arnhem Land visit enabled a strong connection with the Ngukurr community. A passionate collector and restorer of vintage Japanese and classic British motorbikes and Rover cars and belonged to many car clubs. An accomplished mechanic, a captivating teacher and story-teller, a keen fly fisherman and a man with a thirst for adventure John was a distinguished scientist, and citizen.
Obituaries

Prof David John Davies
Late of NSW 1939–2019

Originally from North Wales, David Davies completed his medical degree at the University of Liverpool (UK) which he attended on a scholarship topping undergraduate courses in nine subjects. He held BSc, MB, ChB and MD (by thesis) all from University of Liverpool (U.K.). Migrating with wife Jenny to Australia in 1968, he was a senior lecturer in pathology at Monash University then held roles as Deputy Director, Department of Anatomical Pathology at St Vincent’s Hospital and the University of Melbourne Department of Pathology from 1977–1990. He was awarded FRCPA in 1971. The family moved to Sydney in 1990 for David’s appointment as Director South Western Area Pathology Service (SWAPS) and Conjoint Associate Professor, School of Pathology at UNSW and he became a full Professor from 1995. He was appointed Joint Area Director of Pathology for SSWAHS (2005) and Conjoint Professor of Pathology at the University of Western Sydney (2006).

David was RCPA President (1999-2001) having previously been Vice-President and Chair of the Pathology Professional Activities Committee (PPAC) for 4 years. He chaired the Anatomical Pathology Program of RCPAQAP and was convenor of its general diagnostic module from 2004 and helped introduce whole slide imaging (digital microscopy) for use in quality assurance. David belonged to eleven professional associations and was very active at Federal and State Government level including NPAAC, ACHS, PCC, PSTC. He was a Director of WASPaLM, on the Research Committee of the National SIDS Council, a grants assessor for NHMRC and on the panel of advisers for the Health Care Complaints Commission (HCCC).

At UNSW he developed and maintained the undergraduate program in pathology on the Campus of the Clinical School at Liverpool Hospital and was on the working party on Pathology Teaching for developing the Phase 3 curriculum for the new Medical Course and did similar work for the University of Western Sydney. He was also closely involved with supervision of PhD candidates, hands on teaching at all levels and served as an examiner.

Research areas included the first recognition in 1981 of cytoplasmic antineutrophil cytoplasmic antibody (cANCA) in microscopic polyarteritis nodosa. This has now become a test in general use internationally for diagnosis of small vessel vasculitis. Other interests included pathogenesis of renal medullary necrosis and its relationship to the cortical lesion of chronic intestinal nephritis.

David was responsible for planning and policy in Anatomical Pathology and Microbiology as well as specific duties in the laboratories of the Western Zone of the new Area Health Service (SSWPS), and he took his administrative responsibilities very seriously as it included a large geographic area, big financial operations and services with large numbers of staff.

In 2003 he was awarded the Centenary Medal for services to Australian society and medicine and in 2011 the RCPA Distinguished Fellow Award for his activities in teaching, research, professional practice and administration, he was very proud of both awards. In 2011, the University of NSW Faculty of Medicine named David Overall Conjoint Tutor of the Year in recognition of his commitment to training medical. He will be remembered as someone who made an enormous contribution to the establishment of Liverpool as a teaching hospital and the UNSW pathology teaching in south western Sydney, and invested in state of the art equipment for local clinicians and researchers. He was committed to the College and proud of what he was able to do for the profession through his college work.

David was devoted to his family and was passionate about fly fishing, where he was an expert, able to recall exact details about every fish caught over the years. He also loved model trains and built an amazing working model of trains and countryside in his home. Always the gentleman, despite physical constraints in later years he pressed on and never lost his wonderful dry sense of humour.
Prof Douglas Warrington Henderson, AO
Late of SA 1942-2018

Professor Henderson MB, BS, FRCPA, FRCPath, FHKCPath (Hon) was Professor of Pathology and Head of the Department of Anatomical Pathology at Flinders Medical Centre and the Flinders University of South Australia. During his term on the RCPA Board of Censors (from 1993) he impacted on the thinking of the Board and helped set up the current examination system. Examination formats were revamped and guidelines for examiners offered greater opportunity for a fair and comprehensive assessment of answers.

Doug’s major interests concentrated on asbestos-related disorders, especially lung cancer and malignant mesothelioma, including diagnosis, causation and pathogenesis. He published widely in this area and co-authored a book ‘Malignant Mesothelioma’ (1992) as well as a number of other books and book chapters. He was the SA representative on the Pathology Panel for the Australian Mesothelioma Surveillance Program (AMSP) and the international Mesothelioma Panel as well as a number of other high profile advisory groups. He was awarded for his work in electron microscopy which is acknowledged worldwide and was brought to prominence with the publication of his Atlas and Test Ultrastructural Appearances of Tumours in 1982, followed by a revised edition and second text on Ultrastructural Pathology Diagnostic Ultrastructure of Non-Neoplastic Diseases in 1992. In 1987 Professor Henderson was appointed as an Associate Editor of ‘Ultrastructural Pathology’ and was on the editorial board of the ‘Journal of Pathology’ and ‘The Malaysian Journal of Medical Sciences’.

His achievements and recognition as an international expert in pulmonary and serosal pathology are unquestionable. His significant contributions to the literature in this area and his worldwide status can be appreciated by the appointment to expert committees world-wide. He was an acknowledged Medical Expert witness in legal cases related to pulmonary and mesothelial pathology in many jurisdictions worldwide. At Flinders University he had an active interest in teaching and contributed to the understanding and interpretation of disease processes, especially in the area of diagnostic pathology. An oft-invited speaker on topics of ultrastructural and pulmonary pathology, he was recognised as lucid, well prepared and informative.

Doug personally examined pathology samples from several thousand cases of both malignant mesothelioma and lung cancer, as well as numerous other cases of benign asbestos diseases of various types. He prepared some 4000 medico-legal reports for courts and tribunals in Australia and the UK and was commissioned by solicitors acting for both plaintiffs and respondents, and by the NSW Dust Diseases Board, to prepare reports on diagnosis and causation/attribution.

In 2006 he was awarded a Distinguished Fellow Award by The Royal College of Pathologists of Australasia and in 2010 the Distinguished Pathologist Medal of the Australasian Division of the International Academy of Pathology. In 2015, he was made an Officer in the Order of Australia (AO) for services to medicine, especially in the field of asbestos-related disorders. In October 2016 he was awarded Emeritus Professorial status by the Flinders University.
Obituaries

Dr David Ewen Leslie
Late of Victoria, 1960-2018

David achieved Fellowship in 1992 and served as an examiner in Microbiology for many years. A Medical Microbiologist from the Victorian Infectious Diseases Reference Laboratory (VIDRL) his specific expertise was in mycobacteria and syphilis where he was a leading authority within Australia. He was greatly respected and valued as a source of advice by colleagues locally, and further afield. David’s leadership was always welcoming and encouraging to the many scientists and clinicians that were fortunate enough to work with him.

David’s relationship with VIDRL began in 1990 as a registrar in the Microbiology Department, Fairfield Hospital, now part of VIDRL. He was appointed Medical Microbiologist and Head of the Department of Clinical Pathology in 1993, and Deputy Director of VIDRL in 1995. He was instrumental in the computerisation of the Clinical Pathology Department, and greatly facilitated the unification of Clinical Pathology and Virology in 1993. He had a strong belief in the concept and importance of a public health reference laboratory during a challenging climate of economic rationalism.

David was active in committee work, serving lengthy periods on Victorian advisory committees for tuberculosis, syphilis, and sexually transmitted diseases and blood-borne viruses. He was an expert reviewer for many peer-reviewed journals and a long-standing examiner for the Royal College of Pathologists of Australasia. He also reviewed serology quality assurance programs for RCPAQAP in syphilis, legionella and hydatids. There are a great many clinical microbiologists and infectious diseases physicians around Melbourne and Australia who have spent time as registrars at VIDRL and been supervised by David. That generation of expertise is part of David’s legacy.

After some years in New South Wales, David returned to VIDRL in 2002 as Medical Microbiologist and Head of the Division of Microbiology and Laboratory Services. He resumed his leadership of the Victorian Mycobacterium Reference Laboratory at VIDRL, and his representation on the Victorian Tuberculosis Advisory Committee, and later the Victorian Syphilis Advisory Committee. Syphilis has undergone a resurgence, and David’s expert advice was been in high demand. He foresaw the need for improved syphilis diagnostics and helped introduce syphilis nucleic acid testing at VIDRL, and championed syphilis research. Between 2010 and 2014, as part of VIDRL’s leadership, David contributed to the design of new facilities at the Doherty Institute and the successful move of his group remaining on staff throughout a long battle with illness.

In his personal life, David was an avid bird watcher and nature lover; in later years spending much time on his property on French Island. He also loved cars and enjoyed live music. David will be remembered for his keen intellect, his commitment, and his passion for microbiology.
Prof Timothy John Lyons
Late of NSW, 1954-2019

UK born Tim Lyons medical degree was from Bristol University (1977). He held various hospital appointments gaining experience in coronial autopsies and in 1984 and 1985 worked in Borneo as Medical Officer for an expedition to the caves in Sarawak and then in Cape Town South Africa at the Red Cross Children’s Hospital. Tim left the Sheffield teaching hospitals and his pathology lecturer role at Manchester University in 1994 to take up the post of State Forensic Pathologist in Tasmania and as a lecturer at the University of Tasmania. While there he was involved in rewriting the Coroner’s Act and centralising forensic services. In 2000 the family moved to NSW when Tim joined the Department of Forensic Medicine at Newcastle Hospital. As Director he was instrumental in building up the department over the next 20 years.

A dynamic personality, a passionate teacher, a born optimist and a man with a reportedly ‘warped sense of humour’, he was involved in many sports. His CV covered ‘runner, cyclist, triathlon, kyak, diving, ice hockey. His interests went beyond sporting activities, he loved to travel and over the years was involved in various research projects, for example in ballistics. Interested in all aspects of military medicine, Tim was in the RAAF specialist reserves for 15 years (WGCDR). Tim held a diploma in Aviation Medicine from the University of Otago and had experience in disaster management on an international scale. He completed mountain and cave rescues and had experience of WWII recoveries in PNG and MIA’s in Bouganville, the Port Arthur Massacre victims and recovery after the Bali bombing and the Boxing Day Tsunami.

Often called upon to give evidence in the courts Tim was also a Fellow of the Australian College of Legal Medicine. He had close associations with the legal profession and the police force and was widely respected in those circles. Flamboyant and colourful in every way (he loved colours), he was energetic, a good friend and family man, a mentor and fought hard to the end.
Dr Michael Patrick Metz
Late of South Australia 1955-2018

FRCPA in 2004 Michael was internationally recognised in the field of paediatric and hereditary biochemical disorders. He graduated from the University of Nebraska College of Medicine, trained in paediatrics at the University of Minnesota then moved to Australia to take up a traineeship in chemical pathology at the Women's and Children's Hospital (WCH) and later went to the Institute of Medical and Veterinary Science in Adelaide.

As a dual fellow of the American Academy of Pediatrics and the Royal College of Pathologists of Australasia he was the consultant at the lipid clinic of the WCH in addition to practicing chemical pathology at the WCH site of SA Pathology and at Clinpath Laboratories where he was director of clinical chemistry. He was a member of the advisory board of the Atherosclerosis Australasia Familial Hypercholesterolaemia Registry and was a clinical senior lecturer at the University of Adelaide School of Paediatrics and Reproductive Health.

Michael was passionate about pathology and was widely regarded for his commitment to patient care and teaching in clinical medicine and pathology. It was this philosophy which drew him into our professional activities where he was a Committee Member and later Chair of the SA/NT Branch of the AACB over some 10 years. He was a foundation member of the AACB Paediatric Special Interest Group and former Chair of the RCPA QAP sweat testing working party. He was also active in the Patient Report Commenting program. At the international level Michael was elected a member of the IFCC Task Force on Paediatric Laboratory Medicine (TF-PLM) in 2009, chairing the Task Force over the period 2015-2017. He led the organisation of the 2017 International Congress on Paediatric Laboratory Medicine held in Durban, South Africa which was a great success both for its scientific content and attendance.

His commitment to international activities led to many after midnight conference calls in which he participated with great enthusiasm and without complaint. He always considered the patient at the centre of our pathology practice and did not hesitate to comment to his colleagues if he felt that improvements could be made; staff education was always a high priority for Michael. In addition to his many professional achievements, he was widely recognised for his tenacity, generous spirit and sense of fun.
Obituaries

Prof Howard Morris
Late of South Australia 1946-2019

Professor Morris was an outstanding medical scientist, educator and administrator who made many important contributions to clinical chemistry and laboratory medicine particularly in the area of bone metabolism and vitamin D. His connections with the RCPA were first as an Associate member and later as a Founding Fellow of the Faculty of Science (2010). Howard held a joint appointment as Professor of Medical Science in the School of Pharmacy and Medical Sciences, University of South Australia and Clinical Scientist in Chemical Pathology at SA Pathology, Adelaide Australia.

In 1982 Howard joined the Division of Clinical Biochemistry, at the Institute of Medical and Veterinary Science (now SA Pathology) in charge of the Endocrine Laboratory. As a Clinical Scientist, he had 30 years of experience working in diagnostic clinical biochemistry in the field of immunoassay and endocrinology including management of a major clinical endocrinology laboratory. In recent years most of his efforts went into furthering international focus on quality of the complete test cycle from sample collection to patient outcome. He was able to articulate his message through the many roles he held within the chemical fraternity organisations, both in Australia and internationally including membership of the Federal Councils of the Australian and New Zealand Bone and Mineral Society and the Australasian Association of Clinical Biochemists (AACB). He also represented the AACB on the Councils of the IFCC and the Asian Pacific Federation of Clinical Biochemistry.

Howard was participating in a visiting lecture tour representing the International Federation of Clinical Chemistry (IFCC) at a clinical biochemistry conference in Kazakhstan at the time of his sudden passing.

He had 30 years’ experience working in diagnostic clinical biochemistry in the field of immunoassay and endocrinology including management of a major clinical endocrinology laboratory. In 1997/98, the laboratory reported some 245,000 patient results. Between 2003 and 2009 he was the Director of the Hanson Institute, the research arm of the IMVS and RAH. In 2009 the Hanson Institute administered infrastructure to support the research of some 300 staff and 100 postgraduate students who generated external grants amounting to approximately $AUD 30 million annually.

Professor Morris led an active research team that has received over $10 million in competitive research grants and has published 280 refereed publications, reviews and book chapters. His research interest includes the pathophysiology of metabolic bone disease and the effects of hormones including vitamin D funded by the National Health and Medical Research Council and Australian Research Council, the major competitive funding bodies in Australia. His latest work identified anabolic actions of vitamin D following metabolism within bone tissue providing a molecular mechanism for vitamin D requirement to reduce the risk of fractures amongst the elderly. He was awarded the Louis Avioli Memorial Lectureship for 2009 by the American Society for Bone and Mineral Research on this topic.

Howard was a passionate educator who supervised and mentored numerous local and international honours, Masters and PhD students. He also contributed to the programs of undergraduate teaching at UniSA and the University of Adelaide and was always available to staff and students to help them understand challenging physiology and pathology concepts or discuss issues relating to quality in the pathology laboratory.
Dr John Joseph Sullivan
Late of Queensland 1925-2019

John Joseph Sullivan was born on 29 August 1925 at Southport, Queensland. When he was four years old his mother died and the family was “torn apart”. He and his three sisters went to live with various relatives, John with his grandmother’s sister on a dairy farm at Christmas Creek, near Beaudesert. One day in 1938 the local schoolteacher, who was also living at the farm and thought John “had potential” visited all John’s relatives in the district and collected from 10 of them a total of 50 pounds which was enough to send John to Nudgee College in Brisbane for his first year of high school education. John worked hard and came first in the state in the sub-junior exam, winning a scholarship for the next year. He then topped Queensland in the state-wide junior public exam, winning a further two years at Nudgee. He played football and cricket for Nudgee and in 1942 was school dux, receiving the Collins Cup for leadership in sport and study. Achieving an open scholarship to the University of Queensland he opted for medicine, winning more prizes along the way. Completing this and while a junior doctor at the Brisbane General Hospital, he sat for the physician’s exams. He landed in Pathology at BGH in 1950, “simply because it was the only job going at the time.”

John was 29 when he married fellow university graduate Helen (‘Nell’) Guinn in 1954 and went on to have three children. Marian, the eldest, is a psychiatrist; Edward gained an arts degree but died in 1989; Alice Ann, the youngest, is a neurologist.

On 12 July 1956, John Sullivan acquired the struggling pathology practice of the Brisbane Clinic at 79 Wickham Terrace. Constantly on call for testing, cross matching and resuscitation, he worked all hours of the day and night until Dr Nick Nicolaides joined in 1958 and the practice became Drs JJ Sullivan and NJ Nicolaides Pathologists (later becoming Sullivan Nicolaides Pathology).

He was a founding fellow of the Royal College of Pathologists in 1956 and of the Royal Australasian College of Physicians in 1967. In 1965, he became Vice-President of the Haematology Society of Australia, a fledgling organisation that had formed to host an International Haematological Society meeting in Sydney.

John became increasingly fascinated by the science and practice of Skin Pathology and in 1975 was made an Associate Member of the College of Dermatology and in 1983 was elected President of the Australian Society of Dermatopathology. He inspired David Weedon and other colleagues to also devote their time and careers to Dermatopathology. For over 20 years John tutored University of Queensland pathology students, for 25 he was visiting senior pathologist at Royal Brisbane, and he also served on the Scientific Advisory Committee of the Queensland Cancer Fund.

Dr Sullivan retired from the S&N Partnership in 1990 but worked part-time until 2000. He is fondly remembered with great affection by many colleagues and SNP staff who worked with him – he was a kind and gentle person who with Nick Nicolaides set the personal, professional and ethical standards of SNP that continue until today. He had a true love of his craft and he was an inspirational teacher and leader.

At Pathology Update 2017 the RCPA’s 60th Anniversary was celebrated and John was chosen to represent the founding Fellows of the College. Unable through ill health to be present, a video recording was played at the dinner of John welcoming attendees which was then followed by in person presentations by a Fellow from each of the subsequent decades.

(submitted by Dr Michael Harrison)
Ms Jill Russyll Tate
Late of Queensland 1950-2018

Melbourne born, Jill gained a Bachelor of Science with honours from Monash University (1972) and began publishing papers from that time, produced over 60 papers many with 45 collaborators over the years. The breadth of her scientific publications was considerable and covered transketolase, reference intervals, apolipoproteins, standardisation, poCT, troponin, light chains, and protein electrophoresis. In 1978 she joined AACB in charge of the Enzymes Section and in 1985 received her Master of Science from University of Queensland. Jill was also a member of Clinical Biochemist Reviews and Clinical Chemistry and Laboratory Medicine Editorial Boards.

She was a Founding Fellow of the RCPA Faculty of Science and was closely associated with the Australasian Association of Clinical Biochemists. Her contributions to AACB were recognised with awards of a scholarship, the Outstanding Service Medallion, and later as Roman Lecturer. She was also involved with the International Federation Clinical Chemistry on various committees.

In 1997 Jill was awarded the Nancy Dale Scholarship and began her long association with standardisation of clinical biochemistry assays, publishing on lipoprotein(a) and joining the IFCC standardisation project for the measurement of lipoprotein(a). Subsequently Jill became a member of the IFCC Committee on Standardisation of Markers of Cardiac Damage and Chaired the Working Group for the Standardisation of Cardiac Troponin I. Jill was Associate Editor of Tietz 6th edition and she also compiled an atlas of electrophoretic patterns that is part of the Tietz digital version of the same edition.

Jill made a fundamental contribution to establishing and progressing the national harmonisation initiatives while AACB Vice President of Scientific affairs. An excellent role model and mentor she was interested in promoting young scientists. Known for her modesty, work ethic and organizational skills, she was not without humour, always reliable, generous and thoughtful.
During or since the end of the financial year the College has given an indemnity or entered an agreement to indemnify, or paid or agreed to pay insurance premiums as follows:

The Insurer agrees to pay on behalf of each Insured Person(s) all Loss for which each Insured Person(s) may not be indemnified by the College and which such Insured Person(s) becomes legally obligated to pay on account of any Claim first made against him/her individually or otherwise and notified to the Insurer during the Period of Insurance for a Wrongful Act after the Retroactive Date. For these purposes the Insurer will not be liable to pay where to do so would be prohibitive by law.

Director, Councillor and Officer mean any past, present or future Director, Secretary, Executive Officer or employee of the College.

The company has paid premiums to insure each of the Councillors/Directors against liabilities for costs and expenses incurred by them in defending any legal proceedings arising out of their conduct while acting in the capacity of Councillor/Director of the College, other than conduct involving a wilful breach of duty in relation to the College. The amount of the premium was $12,350 covering all Councillors/ Directors and Officers within Australia and Members of the New Zealand Committee.

Options

The College is not in the practice of issuing share options as it is a Not for Profit organisation.
No person has applied for leave of Court to bring proceedings on behalf of the College or intervened in any proceedings to which the College is a party for the purpose of taking responsibility on behalf of the College for all or any part of those proceedings.

Signed in accordance with a resolution of Directors.

Bruce Latham  
President

Trishe Leong  
Secretary/Treasurer

Dated this 23rd day of September 2019
The Directors of The Royal College of Pathologists of Australasia ("the College") declare that:

1. The financial statements and notes, as set out on the following pages present fairly the College's financial position as at 30 June 2019 and its performance for the 12 month period then ended in accordance with Accounting Standards and other mandatory professional reporting requirements.

2. In the Directors' opinion there are reasonable grounds to believe that the College will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Directors.

Bruce Latham
President

Trishe Leong
Secretary/Treasurer

Dated this 23rd day of September 2019
DECLARATION OF INDEPENDENCE BY GILLIAN SHEA TO THE DIRECTORS OF THE ROYAL COLLEGE OF PATHOLOGISTS OF AUSTRALASIA

As lead auditor of The Royal College of Pathologists of Australasia for the year ended 30 June 2019, I declare that, to the best of my knowledge and belief, there have been:

1. No contraventions of the auditor independence requirements of the Australian professional ethical pronouncements in relation to the audit; and
2. No contraventions of any applicable code of professional conduct in relation to the audit.

Gillian Shea
Partner

BDO East Coast Partnership

Sydney, 23 September 2019
## Statement of Profit or Loss and Other Comprehensive Income

### For the Financial Year Ended 30 June 2019

<table>
<thead>
<tr>
<th>Description</th>
<th>Note</th>
<th>2019 $</th>
<th>2018 $</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subscription, training and fee revenue</td>
<td>3</td>
<td>7,212,439</td>
<td>7,003,627</td>
</tr>
<tr>
<td>Grant revenue</td>
<td>5(b)</td>
<td>15,158,460</td>
<td>12,777,433</td>
</tr>
<tr>
<td>Other revenue</td>
<td>4</td>
<td>3,094,820</td>
<td>4,456,345</td>
</tr>
<tr>
<td>Gain on financial assets held at fair value through profit or loss</td>
<td></td>
<td>175,521</td>
<td>114,575</td>
</tr>
<tr>
<td>Employee benefits expense</td>
<td></td>
<td>(3,817,781)</td>
<td>(3,817,073)</td>
</tr>
<tr>
<td>Depreciation expense</td>
<td>5(a)</td>
<td>(197,198)</td>
<td>(195,360)</td>
</tr>
<tr>
<td>Conferencing/education expense</td>
<td></td>
<td>(1,457,096)</td>
<td>(1,569,006)</td>
</tr>
<tr>
<td>Impairment of trade receivables</td>
<td>5(a)</td>
<td>(37,994)</td>
<td>(84,804)</td>
</tr>
<tr>
<td>Professional fee expense</td>
<td></td>
<td>(824,166)</td>
<td>(912,715)</td>
</tr>
<tr>
<td>Premises expense</td>
<td></td>
<td>(198,863)</td>
<td>(204,367)</td>
</tr>
<tr>
<td>Travel and accommodation expense</td>
<td></td>
<td>(897,513)</td>
<td>(872,239)</td>
</tr>
<tr>
<td>Grant expenses</td>
<td>5(b)</td>
<td>(15,158,460)</td>
<td>(12,777,433)</td>
</tr>
<tr>
<td>Other expenses</td>
<td></td>
<td>(427,457)</td>
<td>(406,552)</td>
</tr>
<tr>
<td>Finance and investment costs</td>
<td>5(a)</td>
<td>(209,153)</td>
<td>(172,183)</td>
</tr>
<tr>
<td><strong>Profit before income tax</strong></td>
<td></td>
<td>2,415,559</td>
<td>3,340,248</td>
</tr>
<tr>
<td><strong>Income tax expense</strong></td>
<td>1(a)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Profit after income tax</strong></td>
<td></td>
<td>2,415,559</td>
<td>3,340,248</td>
</tr>
<tr>
<td><strong>Other comprehensive income:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other comprehensive income income net of income tax</td>
<td></td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total comprehensive income for the year</strong></td>
<td></td>
<td>2,415,559</td>
<td>3,340,248</td>
</tr>
</tbody>
</table>

The accompanying notes form part of these financial statements.
## STATEMENT OF FINANCIAL POSITION

### AS AT 30 JUNE 2019

<table>
<thead>
<tr>
<th>Note</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$</td>
<td>$</td>
</tr>
<tr>
<td><strong>CURRENT ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>6</td>
<td>6,318,857</td>
</tr>
<tr>
<td>Trade and other receivables</td>
<td>7</td>
<td>5,378,405</td>
</tr>
<tr>
<td>Other current assets</td>
<td>8</td>
<td>711,030</td>
</tr>
<tr>
<td>Financial assets</td>
<td>9</td>
<td>12,105,930</td>
</tr>
<tr>
<td><strong>TOTAL CURRENT ASSETS</strong></td>
<td></td>
<td>24,514,222</td>
</tr>
<tr>
<td><strong>NON-CURRENT ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investment in subsidiary company</td>
<td>10</td>
<td>2</td>
</tr>
<tr>
<td>Financial assets</td>
<td>9</td>
<td>7,107</td>
</tr>
<tr>
<td>Property, plant and equipment</td>
<td>11</td>
<td>5,028,509</td>
</tr>
<tr>
<td><strong>TOTAL NON-CURRENT ASSETS</strong></td>
<td></td>
<td>5,035,618</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td></td>
<td>29,549,840</td>
</tr>
<tr>
<td><strong>CURRENT LIABILITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trade and other payables</td>
<td>12</td>
<td>3,342,852</td>
</tr>
<tr>
<td>Short term borrowings</td>
<td>13</td>
<td>18,712</td>
</tr>
<tr>
<td>Short term provisions</td>
<td>14</td>
<td>794,585</td>
</tr>
<tr>
<td>Other current liabilities</td>
<td>12</td>
<td>8,315,715</td>
</tr>
<tr>
<td><strong>TOTAL CURRENT LIABILITIES</strong></td>
<td></td>
<td>12,471,864</td>
</tr>
<tr>
<td><strong>NON-CURRENT LIABILITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Long term borrowings</td>
<td>13</td>
<td>1,560</td>
</tr>
<tr>
<td>Long term provisions</td>
<td>14</td>
<td>172,712</td>
</tr>
<tr>
<td><strong>TOTAL NON-CURRENT LIABILITIES</strong></td>
<td></td>
<td>174,272</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES</strong></td>
<td></td>
<td>12,646,136</td>
</tr>
<tr>
<td><strong>NET ASSETS</strong></td>
<td></td>
<td>16,903,704</td>
</tr>
<tr>
<td><strong>EQUITY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retained earnings</td>
<td></td>
<td>16,903,704</td>
</tr>
<tr>
<td><strong>TOTAL EQUITY</strong></td>
<td></td>
<td>16,903,704</td>
</tr>
</tbody>
</table>

The accompanying notes form part of these financial statements.
### STATEMENT OF CASH FLOWS

FOR THE FINANCIAL YEAR ENDED 30 JUNE 2019

<table>
<thead>
<tr>
<th>Note</th>
<th>2019 $</th>
<th>2018 $</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CASH FLOW FROM OPERATING ACTIVITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Receipts from subscriptions, training and events (inclusive of GST)</td>
<td>9,270,493</td>
<td>7,171,638</td>
</tr>
<tr>
<td>Interest and dividends received</td>
<td>833,009</td>
<td>3,744,907</td>
</tr>
<tr>
<td>Donations received</td>
<td>75,228</td>
<td>331,640</td>
</tr>
<tr>
<td>Grant income received (inclusive of GST)</td>
<td>15,659,152</td>
<td>14,937,946</td>
</tr>
<tr>
<td>Payments to suppliers and employees (inclusive of GST)</td>
<td>(25,152,366)</td>
<td>(20,853,625)</td>
</tr>
<tr>
<td><strong>Net cash provided by operating activities</strong></td>
<td>685,516</td>
<td>5,332,506</td>
</tr>
<tr>
<td><strong>CASH FLOW FROM INVESTING ACTIVITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Payments for property, plant and equipment</td>
<td>(362,741)</td>
<td>(168,030)</td>
</tr>
<tr>
<td>Payments for investments</td>
<td>(1,301,552)</td>
<td>(3,166,713)</td>
</tr>
<tr>
<td><strong>Net cash used in investing activities</strong></td>
<td>(1,664,293)</td>
<td>(3,334,743)</td>
</tr>
<tr>
<td><strong>CASH FLOW FROM FINANCING ACTIVITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Repayment of finance lease commitments</td>
<td>(20,270)</td>
<td>(17,152)</td>
</tr>
<tr>
<td><strong>Net cash used in financing activities</strong></td>
<td>(20,270)</td>
<td>(17,152)</td>
</tr>
<tr>
<td>Net (decrease)/increase in cash held</td>
<td>(999,047)</td>
<td>1,980,611</td>
</tr>
<tr>
<td>Cash at the beginning of the year</td>
<td>7,317,904</td>
<td>5,337,293</td>
</tr>
<tr>
<td><strong>Cash at the end of the year</strong></td>
<td>6,318,857</td>
<td>7,317,904</td>
</tr>
</tbody>
</table>

The accompanying notes form part of these financial statements.
<table>
<thead>
<tr>
<th></th>
<th>General Fund $</th>
<th>ER Fund $</th>
<th>RCPA Foundation $(Note 16)</th>
<th>Total $</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Balance at 1 July 2017</strong></td>
<td>6,836,984</td>
<td>2,813,659</td>
<td>1,497,254</td>
<td>11,147,897</td>
</tr>
<tr>
<td>Profit for the year</td>
<td>54,986</td>
<td>42,003</td>
<td>3,243,259</td>
<td>3,340,248</td>
</tr>
<tr>
<td>Other comprehensive income for the year</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total comprehensive income for the year</strong></td>
<td>54,986</td>
<td>42,003</td>
<td>3,243,259</td>
<td>3,340,248</td>
</tr>
<tr>
<td><strong>Balance at 30 June 2018</strong></td>
<td>6,891,970</td>
<td>2,855,662</td>
<td>4,740,513</td>
<td>14,488,145</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>General Fund $</th>
<th>ER Fund $</th>
<th>RCPA Foundation $(Note 16)</th>
<th>Total $</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Balance at 1 July 2018</strong></td>
<td>6,891,970</td>
<td>2,855,662</td>
<td>4,740,513</td>
<td>14,488,145</td>
</tr>
<tr>
<td>Profit for the year</td>
<td>1,910,053</td>
<td>278,548</td>
<td>226,958</td>
<td>2,415,559</td>
</tr>
<tr>
<td>Other comprehensive income for the year</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total comprehensive income for the year</strong></td>
<td>1,910,053</td>
<td>278,548</td>
<td>226,958</td>
<td>2,415,559</td>
</tr>
<tr>
<td><strong>Balance at 30 June 2019</strong></td>
<td>8,802,023</td>
<td>3,134,210</td>
<td>4,967,471</td>
<td>16,903,704</td>
</tr>
</tbody>
</table>

The accompanying notes form part of these financial statements.
NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2019

1. Significant Accounting Policies

The financial report of The Royal College of Pathologists of Australasia (the College) for the financial year ended 30 June 2019 was authorised for issue in accordance with a resolution of Directors, dated 23rd day of September 2019.

The Directors have prepared the financial statements on the basis that the company is a non-reporting entity because there are no users who are dependent on its general purpose financial statements. These financial statements are therefore special purpose financial statements that have been prepared in order to meet the requirements of the members of the College. The company is a not-for-profit entity for financial reporting purposes under Australian Accounting Standards.

The financial statements have been prepared in accordance with all measurement and recognition criteria, and disclosure requirements of Australian Accounting and the Australian Charities and Not for Profits Commission Act (2012) with the exception of AASB 10 Consolidations and AASB 127 Separate Financial Statements.

The financial statements have been prepared in accordance with the significant accounting policies disclosed below, which the directors have determined are appropriate to meet the needs of members. Such accounting policies are consistent with those of previous periods unless stated otherwise.

The financial statements, except for the cash flow information, have been prepared on an accruals basis and are based on historical costs unless otherwise stated in the notes. Material accounting policies adopted in the preparation of these financial statements are presented below and have been consistently applied unless stated otherwise. The amounts presented in the financial statements are in Australian Dollars which is the College’s functional and presentational currency and have been rounded to the nearest dollar. The financial report has been prepared on a going concern basis.

The following is a summary of the material accounting policies adopted by the College in the preparation of the financial report. The accounting policies have been consistently applied, unless otherwise stated.

(a) Income Tax

The College is classified as a scientific and educational institution by the Australian Taxation Office and therefore, in accordance with section 50-5 of the Income Tax Assessment Act 1997, is exempt from paying income tax.

(b) Property, Plant and Equipment

Items of property, plant and equipment, other than those items noted below, are measured on a cost basis and are depreciated over their estimated useful lives using the straight-line method.

Buildings

The College’s buildings are heritage listed and are being fully maintained. Accordingly, no loss of service potential has occurred during the financial year. Heritage listed buildings have an indefinite life and accordingly, no depreciation has been charged. In addition, as indicated in Note 11 to the financial statements, the carrying value of the land and buildings is at cost and does not exceed their recoverable amount. Independent building valuations are completed every three years.
1. Significant Accounting Policies (continued)

(b) Property Plant and Equipment (continued)

In 2013 an exception was made to this policy for the cost of renovations to the kitchen in Durham Hall. The renovations are estimated to have a useful life of 10 years and are being depreciated on a straight line basis.

Plant and Equipment

Plant and equipment is measured on a cost basis less accumulated depreciation and impairment losses. The carrying amount of plant and equipment is reviewed annually by Directors to ensure that it is not in excess of the recoverable amount from those assets. The recoverable amount is assessed on the basis of the expected net cash flows, which will be received from the asset’s employment and subsequent disposal. The expected net cash flows have not been discounted to present values in determining the recoverable amount.

The Directors of the College do not consider the wall hangings, portraits, presidential medallion and chain, historical books, Maori carved panel and the cedar table to be depreciating assets (that is they are capital appreciating assets) and as such no depreciation has been charged to them. The carrying value of these items is at cost.

Depreciation is charged on straight line basis and the rates used for each class of assets are as follows:

<table>
<thead>
<tr>
<th>Class of fixed asset</th>
<th>Depreciation rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Owned plant and equipment</td>
<td>5 – 40%</td>
</tr>
<tr>
<td>Leased plant and equipment</td>
<td>20%</td>
</tr>
</tbody>
</table>

Web Site Development

The costs of developing the College's web site are recognised as asset and are depreciated over the useful life of the asset. The useful life of the web site is limited due to rapid technological changes and generally would be expected to have a short useful life. Accordingly, a useful life of four years has been adopted for this asset.

(c) Leases

Leases of fixed assets, where substantially all the risks and benefits incidental to the ownership of the asset, but not legal ownership, are transferred to the College and classified as finance leases. Finance leases are capitalised in recording an asset and a liability equal to the present value of the minimum lease payments, including any guaranteed residual values.

Leased assets are depreciated on a straight-line basis over their estimated useful lives where it is likely that the College will obtain ownership of the asset or over the term of the lease. Lease payments are allocated between the reduction of the lease liability and the lease interest expense for the period.

Lease payments under operating leases, where substantially all the risks and benefits remain with the lessor, are charged as an expense through the Statement of Profit or Loss and Other Comprehensive Income on a straight line basis.
1. Significant Accounting Policies (continued)

(d) Financial Instruments

Financial instruments are initially measured at fair value on trade date which includes transaction costs when the related contractual rights or obligations exist. Subsequent to initial recognition, these instruments are measured as set out below.

Financial Assets at Fair Value Through Profit or Loss

Financial assets not measured at amortised cost or at fair value through other comprehensive income are classified as financial assets at fair value through profit or loss. Typically, such financial assets will be either: (i) held for trading, where they are acquired for the purpose of selling in the short-term with an intention of making a profit, or a derivative; or (ii) designated as such upon initial recognition where permitted. Fair value movements are recognised in profit or loss in the period in which they arise.

Loans and Receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market and are stated at amortised cost using the effective rate of interest method.

Financial Liabilities

Non-derivative financial liabilities are recognised at amortised cost using the effective rate of interest method, comprising original debt less principal payments and amortisation.

(e) Foreign Currency Transactions and Balances

Foreign currency transactions during the period are converted to Australian dollars at the rates of exchange applicable at the date of the transaction. Amounts receivable and payable in foreign currencies at the reporting date are converted at the rates of exchange ruling at that date. It is the policy of the College not to hedge their foreign currency transactions.

The gains and losses from conversion of assets and liabilities, whether realised or unrealised, are included in the Statement of Profit or Loss and Other Comprehensive Income as they arise.

(f) Employee Benefits

Short-term employee benefits

Liabilities for wages and salaries, including non-monetary benefits expected to be settled wholly within 12 months after the end of the reporting period are recognised in other liabilities in respect of employees’ services rendered up to the end of the reporting period and are measured at amounts expected to be paid when the liabilities are settled. Liabilities for non-accumulating sick leave are recognised when leave is taken and measured at the actual rates paid or payable.

Other long-term employee benefits

Liabilities for long service leave and annual leave are not expected to be settled wholly within 12 months after the end of the reporting period. They are recognised as part of the provision for employee benefits and measured as the present value of expected future payments to be made in respect of services provided by employees to the end of the reporting period using the projected unit credit method. Consideration is given to expected future salaries and wages levels,
1. Significant Accounting Policies (continued)

(f) Employee Benefits (continued)

experience of employee departures and periods of service. Expected future payments are discounted using national government bond rates at the end of the reporting period with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows.

Regardless of when settlement is expected to occur, liabilities for long service leave and annual leave are presented as current liabilities in the statement of financial position if the entity does not have an unconditional right to defer settlement for at least 12 months after the end of the reporting period.

(g) Cash and Cash Equivalents

For the purpose of the Statement of Cash Flows, cash includes cash on hand and in call deposits with banks or financial institutions, investments in money market instruments maturing within less than three months, net of bank overdrafts.

(h) Comparative Figures

When required by Accounting Standards, comparative figures have been adjusted to conform to changes in presentation for the current financial year.

(i) Borrowing Costs

Borrowing costs are recognised in the Statement of Profit or Loss and Other Comprehensive Income in the period in which they are incurred, unless they are attributable to a qualifying asset when they are capitalised as part of the asset.

(j) Goods and Services Tax (GST)

Revenues, expenses and assets are recognised net of the amount of Goods and Services Tax (GST), except where the amount of GST incurred is not recoverable from the Australian Taxation Office (ATO). In these circumstances, the GST is recognised as part of the cost of acquisition of an asset or as part of the expense.

Receivables and payables in the Statement of Financial Position are shown inclusive of GST.

The net amount of GST recoverable from, or payable to, the ATO is included as a current asset or liability in the Statement of Financial Position.

Cash flows are included in Statement of Cash Flows on a gross basis. The GST component of cash flow arising from investing and financing activities which are recoverable from, or payable to, the ATO are classified as operating cash flows.
NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2019

1. Significant Accounting Policies (continued)

(k) Impairment of Assets

At each reporting date, the College reviews the carrying value of its tangible assets to determine whether there is any indication that those assets have been impaired. If such an indication exists, the recoverable amount of the assets, being the higher of the assets fair value less costs to sell and value in use, is compared to the assets carrying value. Any excess of the assets carrying value over its recoverable amount is expensed to the Statement of Profit or Loss and Other Comprehensive Income.

Where the future economic benefits of the asset are not primarily dependent upon the asset’s ability to generate net cash inflows and when the College would, if deprived of the asset, replace its future economic benefits. Value in use is the depreciated replacement cost of an asset.

(l) Critical Accounting Estimates and Judgements

The Directors evaluate estimates and judgments incorporated into the financial report based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data obtained externally. The key areas where the directors have exercised judgments are: recoverability of trade debtors, the estimated useful life of property, plant and equipment and the provision for long service leave.

(m) Grants

The College receives grant monies to fund projects either for contracted periods of time or for specific projects irrespective of the period of time required to complete those projects. It is the policy of the College to treat grant monies as deferred grant income in the Statement of Financial Position where the entity is contractually obliged to provide the services in a subsequent financial period to when the grant is received or in the case of specific project grants where the performance obligations have not been satisfied.

(n) Revenue Recognition Policy

Revenue from contracts with customers

Revenue is recognised at an amount that reflects the consideration to which the company is expected to be entitled in exchange for transferring goods or services to a customer. For each contract with a customer, the company:
- identifies the contract with a customer;
- identifies the performance obligations in the contract;
- determines the transaction price which takes into account estimates of variable consideration and the time value of money;
- allocates the transaction price to the separate performance obligations on the basis of the relative stand-alone selling price of each distinct good or service to be delivered; and
- recognises revenue when or as each performance obligation is satisfied in a manner that depicts the transfer to the customer of the goods or services promised.

The College recognises revenue from its key revenue streams as follows;

Subscription fee revenue

Subscription fee revenue is recognised over time, as the customer receives and consumes the benefits of fellowship over the course of the period.
1. Significant Accounting Policies (continued)

(n) Revenue Recognition (continued)

Training fee revenue
Training fee revenue is recognised over time, as the customer receives and consumes the benefits of registration for training over the course of the registration period.

Exam fee revenue
Exam fee revenue is recognised at the point in time at which the examination is held, and the performance obligation to the customer is satisfied.

Event revenue
Revenue on event attendance is recognised at the point in time at which the event is held, and the performance obligation to the customer has been satisfied.

Grant revenue
Grant revenue is recognised over time, as the company satisfies its performance obligations as stated in the grant funding agreements.

Other revenue
Other revenue is recognised when it is received or when the right to receive payment is established.

Interest revenue
Interest revenue is recognised as interest accrues, under the effective interest rate method.

(o) New, Revised and Amended Standards and Interpretations

The College has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (‘AASB’) that are mandatory for the current reporting period.

Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted, with the exception of AASB 1058 Income of Not-for-Profit Entities.

The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the College.

The following Accounting Standards and interpretations have been adopted during the period:

AASB 9 Financial Instruments
The company entity has adopted AASB 9 from 1 July 2018. The standard introduced new classification and measurement models for financial assets. A financial asset shall be measured at amortised cost if it is held within a business model whose objective is to hold assets in order to collect contractual cash flows which arise on specified dates and that are solely principal and interest. A debt investment shall be measured at fair value through other comprehensive income if it is held within a business model whose objective is to both hold assets in order to collect contractual cash flows which arise on specified dates that are solely principal and interest as well as selling the asset based on its fair value. All other financial assets are classified and measured at fair value through profit or loss unless the entity makes an irrevocable election on initial recognition to present gains and losses on equity instruments (that are not held-for-trading or contingent consideration recognised in a business combination) in other comprehensive income (‘OCI’). Despite these requirements, a financial asset may be irrevocably designated as measured at fair value through profit or loss to reduce the effect of, or eliminate, an accounting mismatch.
NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2019

1. Significant Accounting Policies (continued)

(o) New, Revised and Amended Standards and Interpretations (continued)

New impairment requirements use an ‘expected credit loss’ (‘ECL’) model to recognise an allowance. Impairment is measured using a 12-month ECL method unless the credit risk on a financial instrument has increased significantly since initial recognition in which case the lifetime ECL method is adopted. For receivables, a simplified approach to measuring expected credit losses using a lifetime expected loss allowance is available.

Policies for measuring financial assets are outlined in Note 1 (d).

The company has adopted AASB 9 during the current period, using the modified retrospective approach, which requires a cumulative catch-up adjustment to retained earnings and no restatement of comparative amounts. No adjustments to any provision for impairment on financial assets have been recognised following the adoption of the expected credit loss model. Further, no adjustments to the classification of financial instruments have been made as a result of the first time adoption of AASB 9 Financial Instruments.

AASB 15 Revenue from Contracts with Customers
This standard is applicable to annual reporting periods beginning on or after 1 January 2018. The standard provides a single standard for revenue recognition. The core principle of the standard is that an entity will recognise revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. It contains a single model that applies to contracts with customers and two approaches to recognising revenue: at a point in time or over time. The model features a contract–based five-step analysis of transactions to determine whether, how much and when revenue is recognised. The standard requires: contracts (either written, verbal or implied) to be identified, together with the separate performance obligations within the contract; determination of the transaction price, adjusted for the time value of money excluding credit risk; allocation of the transaction price to the separate performance obligations on a basis of relative stand-alone selling price of each distinct good or service, or estimation approach if no distinct observable prices exist; and recognition of revenue when each performance obligation is satisfied.

Based on the company’s assessment, the following is noted in relation to its key revenue streams;
- Subscription fees will continue to be recognised over time, as the customer receives and consumes the benefits of fellowship over the course of the period;
- Annual training fees will continue to be recognised over time, as the customer receives and consumes the benefits of registration for training over the course of the registration period;
- Examination fees will continue to be recognised at the point in time at which the examination is held, and the performance obligation to the customer is satisfied;
- Event attendance fees will continue to be recognised at the point in time at which the event is held, and the performance obligation to the customer has been satisfied; and
- Grant revenue will continue to be recognised over time, as the company satisfies its obligation for funding of training posts under the agreement.

Revenue recognition policies are outlined in Note 1 (n).

The company has adopted AASB 15 during the current period, using the modified retrospective approach, which requires a cumulative catch-up adjustment to retained earnings and no restatement of comparative amounts. No material changes are noted to the timing and/or value of revenue recognition under AASB 15, and as such no adjustment has been made to opening retained earnings on transition.
NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2019

1. Significant Accounting Policies (continued)

(o) New, Revised and Amended Standards and Interpretations (continued)

AASB 1058 Income of Not-for-Profit Entities
This standard is applicable to annual reporting periods beginning on or after 1 January 2019. The company has made an election to adopt this accounting standard prior to this required date, in conjunction with the adoption of AASB 15 Revenue from Contracts with Customers. This standard establishes principles for not-for-profit entities, that apply to transactions where consideration to acquire an asset is considerably less than fair value or for the receipt of volunteer services.

This standard is applicable to the company’s receipt of Grant funding, in order to fund various activities in relation to pathology. Based on the company’s assessment, grant income will continue to be recognised over time, as the company satisfied its obligations for the funding of training posts under the agreements in place.

The company has adopted AASB 1058 during the current period, using the modified retrospective approach, which requires a cumulative catch-up adjustment to retained earnings and no restatement of comparative amounts. No material changes are noted to the timing and/or value of revenue recognition under AASB 1058, and as such no adjustment has been made to opening retained earnings on transition.

(p) New accounting standards and interpretations not yet mandatory or early adopted.

Australian Accounting Standards and Interpretations that have recently been issued or amended but are not yet mandatory, have not been early adopted by the company for the annual reporting period ended 30 June 2019. The company’s assessment of the impact of these new or amended Accounting Standards and Interpretations, most relevant to the company, are set out below

AASB 16 Leases
This standard is applicable to annual reporting periods beginning on or after 1 January 2019. To the extent that the entity, as lessee, has significant operating leases outstanding at the date of initial application, right-of-use assets will be recognised for the amount of the unamortised portion of the useful life, and lease liabilities will be recognised at the present value of the outstanding lease payments. Thereafter, earnings before interest, depreciation, amortisation and tax (‘EBITDA’) will increase because operating lease expenses currently included in EBITDA will be recognised instead as amortisation of the right-of-use asset, and interest expense on the lease liability. However, there will be an overall reduction in net profit before tax in the early years of a lease because the amortisation and interest charges will exceed the current straight-line expense incurred under AASB 117 Leases. This trend will reverse in the later years. There will be no change to the accounting treatment for short-term leases less than 12 months and leases of low value items, which will continue to be expensed on a straight-line basis.

The impact of adopting this standard is not expected to have any significant effect on the results of the College.

2. Entity Limited by Guarantee

The College is limited by guarantee under the Corporations Act 2001. The amount of capital, which is capable of being called up, in the event of, and only for the purpose of a winding up of the College, is not to exceed $100 per member by virtue of the College’s Constitution.
## Notes to the Financial Statements

### NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2019

<table>
<thead>
<tr>
<th>Note</th>
<th>2019 $</th>
<th>2018 $</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Subscription, training and fee revenue</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subscriptions</td>
<td>4,258,756</td>
<td>4,125,518</td>
</tr>
<tr>
<td>Other training fees</td>
<td>809,074</td>
<td>771,345</td>
</tr>
<tr>
<td>Examination fees</td>
<td>1,005,799</td>
<td>971,860</td>
</tr>
<tr>
<td>Pathology update conference</td>
<td>1,138,810</td>
<td>1,134,904</td>
</tr>
<tr>
<td></td>
<td><strong>7,212,439</strong></td>
<td><strong>7,003,627</strong></td>
</tr>
<tr>
<td>4. Other revenue</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Earnings from cash holdings and managed funds</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Dividends received</td>
<td>264,608</td>
<td>199,285</td>
</tr>
<tr>
<td>- Interest received</td>
<td>68,401</td>
<td>45,676</td>
</tr>
<tr>
<td>Dividends received from RCPA Quality Assurance Programs Pty Ltd</td>
<td>500,000</td>
<td>2,500,000</td>
</tr>
<tr>
<td>Franking credits</td>
<td>252,111</td>
<td>999,944</td>
</tr>
<tr>
<td>Donations received – RCPA Foundation</td>
<td>75,228</td>
<td>331,640</td>
</tr>
<tr>
<td>Royalties and related income from pathology journal</td>
<td>301,978</td>
<td>332,196</td>
</tr>
<tr>
<td>Payroll tax refund</td>
<td>1,588,727</td>
<td>47,602</td>
</tr>
<tr>
<td>Revenue from other activities</td>
<td>43,767</td>
<td>47,602</td>
</tr>
<tr>
<td></td>
<td><strong>3,094,820</strong></td>
<td><strong>4,456,345</strong></td>
</tr>
<tr>
<td>5. Profit</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(a) Expenses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depreciation of non-current owned assets</td>
<td>178,507</td>
<td>176,669</td>
</tr>
<tr>
<td>Depreciation of non-current leased assets</td>
<td>18,691</td>
<td>18,691</td>
</tr>
<tr>
<td></td>
<td><strong>197,198</strong></td>
<td><strong>195,360</strong></td>
</tr>
<tr>
<td>Impairment of trade receivables</td>
<td>37,994</td>
<td>84,804</td>
</tr>
<tr>
<td>Finance and investment costs:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Merchant charges for credit card facility</td>
<td>103,029</td>
<td>93,015</td>
</tr>
<tr>
<td>Investment charges</td>
<td>107,119</td>
<td>70,860</td>
</tr>
<tr>
<td>Bank fees and charges</td>
<td>3,957</td>
<td>4,790</td>
</tr>
<tr>
<td>Unrealised foreign exchange variation</td>
<td>(4,952)</td>
<td>3,518</td>
</tr>
<tr>
<td></td>
<td><strong>209,153</strong></td>
<td><strong>172,183</strong></td>
</tr>
</tbody>
</table>
5. Profit (continued)

(b) Significant Revenues and Expenses

The following revenue and expenses are relevant in explaining the financial performance of the College:

Included in revenue and other expenses per the Statement of Profit or Loss and Other Comprehensive Income are the following revenues and expenses resulting from specific grants received by the College. Grant revenue is recognised as expenses are incurred, any excess of Grant receipts over Grant expenses is recognised in the Statement of Financial Position as Deferred Grant Income. Unexpended Grant income is returned to the Grant provider.

<table>
<thead>
<tr>
<th>Grant</th>
<th>Revenues</th>
<th>Expenses</th>
<th>Deferred Grant Income</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grant – Standardisation of Pathology Information Terminology and units (third grant)</td>
<td>239,064</td>
<td>275</td>
<td>328,658</td>
</tr>
<tr>
<td>Grant – Pathology Workforce Change - National Cervical Screening Program</td>
<td>-</td>
<td>230,773</td>
<td>18,882</td>
</tr>
<tr>
<td>Grant – Structured Reporting of Cancer funding for an additional protocol</td>
<td>-</td>
<td>-</td>
<td>2,565</td>
</tr>
<tr>
<td>Grant – Health Genomics Stage 1 &amp; 2</td>
<td>26,937</td>
<td>153,676</td>
<td></td>
</tr>
<tr>
<td>Grant – Structural Pathology Reporting of Cancer 2016</td>
<td>222,170</td>
<td>174,732</td>
<td>253,709</td>
</tr>
<tr>
<td>Grant – Common Sense Pathology</td>
<td>83,167</td>
<td>-</td>
<td>230,333</td>
</tr>
</tbody>
</table>
NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2019

5. Profit (continued)

(b) Significant Revenues and Expenses (continued)

<table>
<thead>
<tr>
<th>Grant – Specialist Training Program 2010</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>183</td>
<td>6,635,330</td>
</tr>
<tr>
<td>Expenses</td>
<td>183</td>
<td>6,635,330</td>
</tr>
<tr>
<td>Deferred Grant Income</td>
<td>-</td>
<td>153,636</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Grant – Specialist Training Program – Tasmania 2010</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>-</td>
<td>498,863</td>
</tr>
<tr>
<td>Expenses</td>
<td>-</td>
<td>498,863</td>
</tr>
<tr>
<td>Deferred Grant Income</td>
<td>-</td>
<td>125,677</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Grant – Genetic and Genomic Certification</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>18,736</td>
<td>-</td>
</tr>
<tr>
<td>Expenses</td>
<td>18,736</td>
<td>-</td>
</tr>
<tr>
<td>Deferred Grant Income</td>
<td>222,335</td>
<td>-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Grant – Specialist Training Program – Tasmania 2018</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>576,968</td>
<td>290,331</td>
</tr>
<tr>
<td>Expenses</td>
<td>576,968</td>
<td>290,331</td>
</tr>
<tr>
<td>Deferred Grant Income</td>
<td>156,527</td>
<td>72,934</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Grant - Specialist Training Program 2018</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues</td>
<td>13,991,235</td>
<td>4,793,453</td>
</tr>
<tr>
<td>Expenses</td>
<td>13,991,235</td>
<td>4,793,453</td>
</tr>
<tr>
<td>Deferred Grant Income</td>
<td>1,031,966</td>
<td>1,991,702</td>
</tr>
</tbody>
</table>

Total Grant Revenues                     | 15,158,460 | 12,777,433 |
Total Grant Expenses                     | 15,158,460 | 12,777,433 |
Total Deferred Grant Income              | 2,244,975  | 3,167,841  |
## Notes to the Financial Statements

### FOR THE FINANCIAL YEAR ENDED 30 JUNE 2019

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>6. Cash and Cash Equivalents</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash at bank</td>
<td>6,318,357</td>
<td>7,317,404</td>
</tr>
<tr>
<td>Cash on hand</td>
<td>500</td>
<td>500</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>6,318,857</td>
<td>7,317,904</td>
</tr>
</tbody>
</table>

| **7. Trade and Other Receivables** |            |            |
| **Current**               |            |            |
| Trade receivables        | 5,812,324  | 4,822,453  |
| Less: allowance for expected credit losses | (437,500) | (399,506) |
| **Total**                | 5,374,824  | 4,422,947  |
| Amounts receivable from related parties (Note 21) | 3,581     | 4,912      |
| **Total**                | 5,378,405  | 4,427,859  |

| **8. Other Current Assets** |            |            |
| Prepayments               | 550,682    | 311,960    |
| Cash held on behalf of State Committees | 160,348   | 157,324    |
| **Total**                 | 711,030    | 660,287    |

The Cash held on behalf of State Committees, its ultimate ownership rests with the College. State Committees have discretion over the use of this cash.

| **9. Financial Assets** |            |            |
| **Current**             |            |            |
| Managed Investments at fair value through profit or loss |            |            |
| - Alternative investments | 5,535,708 | 3,057,910 |
| - Cash and fixed income – securities | 4,466,260 | 5,478,558 |
| - Equities (shares and similar investments) | 2,103,962 | 2,092,390 |
| **Total**               | 12,105,930 | 10,628,857 |

| **Non-Current**         |            |            |
| Shares in listed corporations |            |            |
| - At cost               | 7,107      | 7,107      |
| **Total**               | 7,107      | 7,107      |

| **10. Investments in subsidiary company** |            |            |
| RCPA Quality Assurance Programs Pty Ltd - 2 Ordinary shares fully paid | 2 | 2 |

| **Total** | 2 | 2 |
## Notes to the Financial Statements

### NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2019

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>11. Property, Plant and Equipment</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Property</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Land and building improvements</td>
<td>279,547</td>
<td>182,951</td>
</tr>
<tr>
<td>Less: accumulated depreciation</td>
<td>(102,711)</td>
<td>(81,747)</td>
</tr>
<tr>
<td>Land and buildings – at cost [refer note 1 (b)]</td>
<td>4,453,127</td>
<td>4,301,113</td>
</tr>
<tr>
<td>Less: impairment</td>
<td>(148,185)</td>
<td>(148,185)</td>
</tr>
<tr>
<td><strong>Total property</strong></td>
<td>4,481,778</td>
<td>4,254,132</td>
</tr>
</tbody>
</table>

| **Plant and Equipment – General Fund** |        |        |
| Office furniture – at cost          | 351,391 | 341,157 |
| Less: accumulated depreciation      | (228,242) | (192,922) |
| **Office equipment and machines – at cost** | 123,149 | 148,235 |
| Less: accumulated depreciation      | (450,200) | (412,130) |
| **Wall hangings – at cost**         | 4,135   | 4,135   |
| **Maori carved panel – at cost**    | 4,750   | 4,750   |
| **Computer equipment – at cost**    | 2,013,737 | 1,937,550 |
| Less: accumulated depreciation      | (1,830,270) | (1,748,467) |
| **Leased assets – at cost**         | 93,558  | 93,558  |
| Less accumulated amortisation      | (70,104) | (51,413) |
| **Honour boards – at cost**         | 6,682   | 6,682   |

| **Plant and Equipment – Education and research Fund** |        |        |
| **Portraits – at cost**                   | 2,565   | 2,565   |
| **Historical books – at cost**            | 4,595   | 4,595   |
| **Cedar table – at cost**                 | 4,700   | 4,700   |
| **Medals – at cost**                      | 1,575   | 1,575   |
| **Total Plant and Equipment**             | 546,731 | 606,719 |

| **Work in progress**                     |        |        |
| **Total Property, Plant and Equipment**  | 5,028,509 | 4,862,966 |
NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2019

11. Property, Plant and Equipment (continued)

(a) Movement in carrying amounts

Movement in the carrying amounts for each class of property, plant and equipment between the beginning and end of the current year are as follows:

<table>
<thead>
<tr>
<th></th>
<th>Land and Buildings $</th>
<th>Computer Equipment &amp; Software $</th>
<th>Plant, Equipment &amp; Furniture $</th>
<th>Work in progress - Building $</th>
<th>Leased Assets $</th>
<th>Total $</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balance at beginning of year</td>
<td>4,254,132</td>
<td>189,083</td>
<td>375,491</td>
<td>2,115</td>
<td>42,145</td>
<td>4,862,966</td>
</tr>
<tr>
<td>Additions</td>
<td>246,495</td>
<td>78,536</td>
<td>37,710</td>
<td>0</td>
<td>0</td>
<td>362,741</td>
</tr>
<tr>
<td>Transfers</td>
<td>2,115</td>
<td>-</td>
<td>-</td>
<td>(2,115)</td>
<td>0</td>
<td>(2,115)</td>
</tr>
<tr>
<td>Disposals</td>
<td>0</td>
<td>-</td>
<td>-</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Depreciation expense</td>
<td>(20,964)</td>
<td>(84,152)</td>
<td>(73,391)</td>
<td>(2,115)</td>
<td>0</td>
<td>(197,198)</td>
</tr>
<tr>
<td>Carrying amount at the end of year</td>
<td>4,481,778</td>
<td>183,467</td>
<td>339,810</td>
<td>0</td>
<td>23,454</td>
<td>5,028,509</td>
</tr>
</tbody>
</table>

(b) Recoverable amount of land and buildings

The Directors obtained professional advice from a valuer to ascertain the current market value of the freehold property owned by the College at 203-205 Albion Street, Surry Hills. The advice received was a formal valuation dated June 2019. Based on the valuation provided, the property has a market value of $5.6 million. This valuation takes into account the age and condition of the property, recent comparable sales and the fact that the property is heritage listed. The above value does not include costs of realisation, estimated to be in the range of 3% to 4%. The carrying value of the property is $2.952 million as at 30 June 2019.

The Directors considered the valuation of the property owned by the College at 207 Albion Street, Surry Hills and obtained professional advice from a valuer to ascertain the current market value. The advice received was a formal valuation dated June 2019. Based on the valuation provided, the property has a current market value of $7.3 million. This valuation takes into account the age and condition of the property, recent comparable sales and the fact that it is heritage listed. The above value does not include costs of realisation, estimated to be in the range of 3% to 4%. The carrying value of the property is $1.35 million as at 30 June 2019.

As such the Directors are satisfied that the recoverable amount of land and buildings exceeds the carrying value, and therefore no impairment is required for the year ending 30 June 2019.
NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2019

12. Trade and Other Payables

<table>
<thead>
<tr>
<th>Category</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current (unsecured)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trade creditors</td>
<td>339,696</td>
<td>295,449</td>
</tr>
<tr>
<td>Accruals</td>
<td>2,361,233</td>
<td>2,338,617</td>
</tr>
<tr>
<td>Other current payables</td>
<td>641,923</td>
<td>579,894</td>
</tr>
<tr>
<td><strong>Total trade and other payables</strong></td>
<td>3,342,852</td>
<td>3,213,960</td>
</tr>
<tr>
<td>Other Current Liabilities (unsecured)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grant income deferred</td>
<td>2,244,975</td>
<td>3,167,841</td>
</tr>
<tr>
<td>Funds committed for special purpose projects</td>
<td>822,922</td>
<td>1,126,144</td>
</tr>
<tr>
<td>Revenue received in advance</td>
<td>5,247,818</td>
<td>4,934,197</td>
</tr>
<tr>
<td><strong>Total other liabilities</strong></td>
<td>8,315,715</td>
<td>9,228,182</td>
</tr>
</tbody>
</table>

13. Borrowings

<table>
<thead>
<tr>
<th>Category</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current (secured)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lease liability (Note 15)</td>
<td>18,712</td>
<td>18,712</td>
</tr>
<tr>
<td>Non-Current (secured)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lease liability (Note 15)</td>
<td>1,560</td>
<td>21,830</td>
</tr>
<tr>
<td><strong>Total current and non-current secured liabilities</strong></td>
<td>20,272</td>
<td>40,542</td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th>Category</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Employee benefits:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opening balance</td>
<td>746,527</td>
<td>737,353</td>
</tr>
<tr>
<td>Movements during the year</td>
<td>48,058</td>
<td>9,174</td>
</tr>
<tr>
<td>Closing balance</td>
<td>794,585</td>
<td>746,527</td>
</tr>
<tr>
<td>Non-Current</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Employee benefits:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opening balance</td>
<td>187,626</td>
<td>185,180</td>
</tr>
<tr>
<td>Movements during the year</td>
<td>(14,914)</td>
<td>2,446</td>
</tr>
<tr>
<td>Closing balance</td>
<td>172,712</td>
<td>187,626</td>
</tr>
<tr>
<td><strong>Aggregate employee benefit liability</strong></td>
<td>967,297</td>
<td>934,153</td>
</tr>
</tbody>
</table>

Provision for Non-Current Employee Benefits
A provision has been recognised for employee entitlements relating to long service leave. In calculating the present value of future cash flows in respect of long service leave, the probability of long service leave taken is based on historical data. The measurement and recognition criteria relating to employee benefits have been included in Note 1 of this financial report.
15. Capital and Lease Commitments

(a) Finance Lease Commitments Payable:

- Not later than one year: $18,712
- Later than one year but not later than five years: $1,560
Minimum lease payments: $20,272
Total lease liability: $20,272

The finance lease on office plant and equipment, which commenced in September 2015, is a 5-year lease. The lease payments are paid monthly in advance. The security for this lease is the asset being leased under this arrangement.

(b) Operating Lease Commitments Payable:

The College has operating lease commitments payable as at 30 June 2019 of $30,870 (2018: $6,760).

- No later than one year: $7,124
- Later than two years but no later than five years: $23,746
Total operating lease commitments: $30,870

(c) Capital Expenditure

The College has no commitments for capital expenditure at the date of this report.

16. RCPA Foundation for Education and Research

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opening balance</td>
<td>4,740,513</td>
<td>1,497,254</td>
</tr>
<tr>
<td>Donations received</td>
<td>75,228</td>
<td>331,641</td>
</tr>
<tr>
<td>Investment income</td>
<td>122,169</td>
<td>59,672</td>
</tr>
<tr>
<td>Dividends received</td>
<td>106,373</td>
<td>2,967,107</td>
</tr>
<tr>
<td>Grants awarded</td>
<td>(43,509)</td>
<td>(99,711)</td>
</tr>
<tr>
<td>Expenses</td>
<td>(33,303)</td>
<td>(15,450)</td>
</tr>
<tr>
<td>Total income for the year</td>
<td>226,958</td>
<td>3,243,259</td>
</tr>
<tr>
<td>Closing balance</td>
<td>4,967,471</td>
<td>4,740,513</td>
</tr>
</tbody>
</table>

Represented by:
Cash at bank: $90,868, 19,776
Managed investments: $4,876,603, 4,720,737
Total fund: $4,967,471, 4,740,513
NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2019

16. RCPA Foundation for Education and Research (continued)

The RCPA Foundation for Education and Research was established as a College fund in 2012. The fund was created from donations received specifically to support grants and other forms of assistance for Pathologists and Scientists undertaking further education and relevant research.

The College Board of Directors has formed an independent committee to administer the RCPA Foundation for Education and Research.

17. Remuneration of Directors

The Directors of the College received no remuneration or benefits during the financial year (2018: nil).

Directors have been in office since the start of the financial year to the date of this report unless otherwise stated.

Dr Roger Wilson (resigned November 2018)  Prof Anthony Landgren
Dr Michael Dray  Dr Merrole Cole-Sinclair (resigned Nov. 2018)
Dr Lawrence Bott (resigned November 2018)  Dr Janet Kencian (resigned November 2018)
Dr Bruce Latham  Prof John Burnett
Dr Nicole Kramer  Dr Trishe Leong (appointed November 2018)
Dr Daniel Owens (appointed November 2018)  Dr Lynette Waring (appointed November 2018)
Dr Daman Langguth (appointed November 2018)

18. Key Management Personnel Remuneration

The total compensation of key management personnel is as follows:

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aggregate compensation</td>
<td>$602,873</td>
<td>$717,070</td>
</tr>
</tbody>
</table>
19. Contingent Liabilities

The Directors of the College are not aware of any contingent liabilities as at 30 June 2019 (2018: Nil).

20. Events Subsequent to Reporting Date

In August 2019 the company received a refund of the payroll tax paid since 2011 after the NSW Office of State Revenue confirmed that the company was exempt from paying this tax. After assessing the impact of the transaction, it has been recorded in these financial statements. The refund received was $1,588,727 and after accounting for related professional fees the net receipt was $1,389,836. Otherwise, no matters or circumstance has arisen since 30 June 2019 that has significantly affected, or may significantly affect the College's operations, the results of those operations, or the College's state of affairs in future financial years.

21. Related Party Transactions

During the year the College entered into the following transactions with the following entities.

<table>
<thead>
<tr>
<th>Description</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Administration charge contribution from RCPA QAP</td>
<td>170,918</td>
<td>165,267</td>
</tr>
<tr>
<td>Cost recovery from ICCR</td>
<td>118,537</td>
<td>77,898</td>
</tr>
<tr>
<td>Dividend received from RCPA QAP</td>
<td>500,000</td>
<td>2,500,000</td>
</tr>
<tr>
<td>Amount receivable from / (owing to) RCPA QAP at balance date</td>
<td>980</td>
<td>2,356</td>
</tr>
<tr>
<td>Amount owed by ICCR at balance date</td>
<td>2,601</td>
<td>2,556</td>
</tr>
</tbody>
</table>

Term of payment for RCPA QAP and ICCR is 30 days from the date of invoice.

RCPA QAP, full name RCPA Quality Assurance Programs Pty Limited, was established under a Trust Deed set up by the Council of the College. The members of the QAP Board of Directors are Fellows of the College. From 1 July 2015 QAP became a subsidiary company wholly owned by the College.

ICCR, full name International Collaboration for Cancer Reporting Limited, was established as a company limited by guarantee in 2014. The College is a founding member of ICCR and has permanent representation on the board of directors.
NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2019

22. Cash Flow Information

(a) Reconciliations of Cash

<table>
<thead>
<tr>
<th>Item</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash at bank</td>
<td>6,318,357</td>
<td>7,317,404</td>
</tr>
<tr>
<td>Cash on hand</td>
<td>500</td>
<td>500</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>6,318,857</strong></td>
<td><strong>7,317,904</strong></td>
</tr>
</tbody>
</table>

(b) Reconciliation of Profit after Income Tax to Net Cash from Operating Activities

<table>
<thead>
<tr>
<th>Item</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Profit after income tax</td>
<td>2,415,559</td>
<td>3,340,248</td>
</tr>
<tr>
<td>Non-cash flows in profit</td>
<td>197,198</td>
<td>195,360</td>
</tr>
<tr>
<td>Depreciation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Loss on sale of fixed assets</td>
<td>-</td>
<td>1,256</td>
</tr>
<tr>
<td>Impairment of trade receivables</td>
<td>37,994</td>
<td>84,804</td>
</tr>
<tr>
<td>Fair value gain on financial assets through to profit or loss</td>
<td>(175,521)</td>
<td>(114,575)</td>
</tr>
<tr>
<td>Changes in assets and liabilities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increase in trade and other receivables</td>
<td>(988,540)</td>
<td>(1,277,344)</td>
</tr>
<tr>
<td>Increase in other assets</td>
<td>(50,743)</td>
<td>(183,354)</td>
</tr>
<tr>
<td>Increase in trade and other payables</td>
<td>128,892</td>
<td>2,090,889</td>
</tr>
<tr>
<td>Increase in provisions</td>
<td>33,144</td>
<td>11,620</td>
</tr>
<tr>
<td>(Decrease)/Increase in other liabilities</td>
<td>(912,467)</td>
<td>1,183,602</td>
</tr>
<tr>
<td>Net cash provided by operating activities</td>
<td>685,516</td>
<td>5,332,506</td>
</tr>
</tbody>
</table>
INDEPENDENT AUDITOR’S REPORT

To the members of The Royal College of Pathologists of Australasia


Opinion

We have audited the financial report of The Royal College of Pathologists of Australasia (the registered entity), which comprises the statement of financial position as at 30 June 2019, the statement of profit or loss and other comprehensive income, the statement of changes in equity and the statement of cash flows for the year then ended, and notes to the financial report, including a summary of significant accounting policies, and the responsible entities’ declaration.

In our opinion the accompanying financial report of The Royal College of Pathologists of Australasia, is in accordance with Division 60 of the Australian Charities and Not-for-profits Commission Act 2012, including:

(i) Giving a true and fair view of the registered entity’s financial position as at 30 June 2019 and of its financial performance for the year then ended; and

(ii) Complying with Australian Accounting Standards to the extent described in Note 1 and Division 60 of the Australian Charities and Not-for-profits Commission Regulation 2013.

Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the Financial Report section of our report. We are independent of the registered entity in accordance with the auditor independence requirements of the Australian Charities and Not-for-profits Commission Act 2012 (ACNC Act) and the ethical requirements of the Accounting Professional and Ethical Standards Board’s APES 110 Code of Ethics for Professional Accountants (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of matter – Basis of accounting

We draw attention to Note 1 to the financial report, which describes the basis of accounting. The financial report has been prepared for the purpose of fulfilling the registered entity’s financial reporting responsibilities under the ACNC Act. As a result, the financial report may not be suitable for another purpose. Our opinion is not modified in respect of this matter.

Other information

Those charged with governance are responsible for the other information. The other information obtained at the date of this auditor’s report is information included in the registered entity’s annual report, but does not include the financial report and our auditor’s report thereon.
Independent Auditor’s Report

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed on the other information obtained prior to the date of this auditor’s report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of responsible entities for the Financial Report

The responsible entities of the registered entity are responsible for the preparation of the financial report that gives a true and fair view and have determined that the basis of preparation described in Note 1 to the financial report is appropriate to meet the requirements of the ACNC Act and the needs of the members. The responsible entities’ responsibility also includes such internal control as the responsible entities determine is necessary to enable the preparation of a financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the responsible entities are responsible for assessing the registered entity’s ability to continue as a going concern, disclosing, as applicable, matters relating to going concern and using the going concern basis of accounting unless the responsible entities either intend to liquidate the registered entity or to cease operations, or have no realistic alternative but to do so.

Auditor’s responsibilities for the audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website (http://www.auasb.gov.au/Home.aspx) at:


This description forms part of our auditor’s report.

BDO East Coast Partnership

Gillian Shea
Partner

Sydney, 23 September 2019